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General Introduction: The field of geriatric oncology 
 
1. The paradox: senescence protects against cancer, and causes cancer 
a. Cellular senescence – aging and cancer 
 
The biological process of aging is a complex mechanism. It is not reducible to a single 
physiological change in the organism, but it concerns a multifactorial process. A lot of research has 
already been performed on the topic, and various physiological age-related changes have been 
identified. 
Cellular senescene is thought to represent one of the capital molecular processes in biological aging. 
It serves primarily as a protection mechanism that shuts down damaged cells. They are forced into a 
state of irreversible growth arrest1,2. Senescent cells are characterized by a specific phenotype 
(enlarged size, flattened morphology, senescence associated β-galactosidase activity, reorganization 
of chromatin into foci of herterochromatin and resistance to apoptosis)3 (Fig 1).  
 
 
 
A 
            B 
 
 
 
 
Figure 1: (A) Schematic representation of the transition of a normal cell to a senescent cell, (B) microscopic features 
of normal cells versus senescent cells after staining for β-galactosidase activity (www.sigmaaldrich.com; 
catalogue#CS0030) 
 
 
 
 
 
 
Normal	cell	
Senescent	cell	
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Triggers that induce the senescence program are various: telomere erosion, unresolved DNA 
damage, lysosomal stress, unresolved UPR (unfolded protein response), oncogene activation, 
culture shock or reactive oxygen species4. The induction of senescence in a damaged cell protects 
the organism from developing cancer, as it is characterized by unability to re-enter the cell division 
cycle in response to mitogens and by an acquired resistance to oncogenic stimulation. Thereby, it 
prevents damaged cells from uncontrolled proliferation and dissemination. Senescence is therefore 
believed to be an evolutionary selected mechanism that preserves the integrity of the young 
organism during reproductive lifespan (Fig 2). 
  
Figure 2: Adapted from Shan et all 5 
The two-sided face of senescence: protection against 
cancer and aging.  
Normal tissue cells can be initiated towards a 
preneoplastic state by several triggers (telomere 
erosion, DNA damage, oncogene activation, …). 
Activation of TP53, p16, and RB gene induce 
senescence in this cell, preventing it from turning 
into a cancerous lesion. Whereas this mechanism 
protects from cancer in young life, it causes aging in 
older life. If this mechanism of senescence is 
bypassed through additional (epi-)genetic changes, 
preneoplastic cells can evolve towards a malignant 
tumor. 
 
 
Senescence is induced through upregulation of several senescence genes, the most robust genes 
being CDKN2A (p16/INK4A/ARF), TP53, RB (Retinoblastoma gene). A fourth gene, CDKN1A 
(p21/WAF1/CIP1), has also a role in inducing growth arrest, but is a less reliable senescence 
marker, as the growth arrest induced by upregulation of this gene can be more transient4.  
The pathway by which these genes induce cell cycle arrest is depicted in figure 3, taken from one of 
our own publications6. 
CDKN2A is a complex gene that encodes two distinct proteins, p16INK4a and p14ARF. Despite arising 
from the same gene, there is no protein sequence similarity between these products.  The locus has a 
complex architecture, containing two separate promoters that generate transcripts with different first 
exons followed by common second and third exons. Because the shared exons are read in different 
reading frames they are not isoforms and have no amino acid homology. p16INK4a is encoded by 
Telomere	erosion,	DNA	damage,	
oncogene	ac1va1on,	…	
Normal	Tissue	
Ini1ated	Cell	
Addi1onal	Oncogenic	Stress,	
silencing	of	senescence	genes	
Bypass	of	Senescence	P53	-	p16/pRB	ac1va1on	
Senescence	
Malignant	Transforma1on	Cancer	preven1on	in	Young	 Aging	in	Old	
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exons 1α, 2, and 3. It functions as a cyclin-dependent kinase inhibitor of the cell cycle by inhibiting 
the activity of the cyclin-dependent kinase complex “cyclin D/CDK4/CDK6”, thereby inhibiting the 
pRB phosphorylation and blocking the passage from G1 into S 7,8. The alternate reading frame 
product, p14ARF, is encoded by a different first exon (exon 1β) that is upstream of exon 1α, using 
the same second exon as p16INK4a but in a different reading frame8. The amino-acid coding 
sequence of p14ARF ends in exon 2, with the remainder of exon 2 and exon 3 comprising the 3'-
untranslated region9. p14ARF functions by preventing p53 degradation, thereby allowing p53-
mediated apoptosis or cell cycle arrest. 
 
 
Figure 3: Reprinted with permission from Elsevier.  
The p16 locus and cell cycle control. 
The p16 locus encodes 2 overlapping proteins, p16 and 
ARF, by using different first exons and common 
second and third exons. These structurally very 
different proteins both act as negative regulators of the 
cell cycle, p16 inhibits the activation of CDK4 and 
CDK6 by cyclin D, hence preventing subsequent 
phosphorylation of pRB and thus cell cycle 
progression. ARF regulates p53 activity by binding 
with MDM2, an ubiquitin ligase that otherwise targets 
p53 for its degradation by proteasome. High levels of 
ARF stabilize p53 permitting it to induce p21, a cell 
cycle inhibitor that blocks CDK2/cyclin E  – mediated 
phosphorylation of pRB. 
 
Lately, also PTEN has come across as a potential candidate gene involved in senescence10. PTEN is 
an established tumor suppressor gene. Very often it is mutated in human tumors11. Recent 
transgenic mouse models have highlighted a role in the aging process as well12,13. The two mouse 
models display systemic PTEN overexpression, but under normal regulatory control. These mice 
exhibit, next to reduced adiposity and metabolic changes, higher median and maximal lifespans, 
independent of the tumor suppressor function of PTEN. 
In the past, downregulation of the nutrient sensing IIS (Insulin/insulin-like growth factor signaling) 
pathway has been shown to be a main modulator of longevity conserved across evolution (cfr 
lifespan extension of organisms through caloric restriction). The observation that PTEN 
overexpression in mice extends their lifespan, adds further evidence to this paradigm 
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However, there seems to be a price to pay for this protection mechanism. In exchange for 
organismal integrity in younger life, accumulation of senescent cells throughout the body causes 
biological aging in older life. According to a current hypothesis, which originated from the finding 
that senescent cells accumulate in vitro with increasing population doublings until the majority of 
the culture has reached replicative senescence, senescent cells accumulate in the organism and due 
to their lack of regenerative capacity, this results in failure of organ homeostasis and function and, 
consequently, tissue aging14. Senescent cells have been reported in vivo, in a variety of tissues of 
different organisms including mouse, primates and humans15-19. Also have there been studies 
providing evidence that increasing age does result in a higher frequency of senescent cells15-17,20, be 
it mostly in skin. The identification of signs of senescence at specific sites of age-related 
pathologies, further suggests the link between cellular senescence and aging21-24. 
 
The dual role of senescence genes (Fig 2) in aging and cancer is further illustrated by progeroid 
syndromes (e.g. Werner’s syndrome, Hutchinson-Gilford progeria syndrome). These are 
characterized by defects in DNA repair mechanisms. As the naturally occurring DNA damage in 
these patients is not repaired correctly, the patients develop severe aging sings at young age, 
because of widespread activation of senescence and/or apoptosis in damaged cells. Some of these 
syndromes, like Werner’s syndrome, are also characterized by high risk of developing cancer at 
young age.  
 
Furthermore, the trade-off between cancer and aging has been nicely illustrated by impressive mice-
experiments, where TP53 was manipulated in order to observe the effects on the aging process and 
the development of cancer: mice with one knock-out allele of TP53, died mostly because of cancer. 
If however, they happened to escape from cancer, they displayed a longer lifespan than normal 
counterparts, showing that decreased occurrence of senescence restrains aging. Mice transfected 
with a constitutively active allele of TP53, had a greatly reduced cancer incidence, but showed 
premature aging. If mice were armed with an extra allele of TP53, but under normal control (so not 
constitutively activated), they did not show this enhanced aging phenotype, but did however have 
improved tumor clearance.25-29 
 
b. Tissue aging  
 
The process of molecular senescence is a general concept potentially occurring in every cell type. 
Nevertheless, some tissues or organs seem more prone to accumulate senescent cells, and others do 
only contain sporadic senescent cells even after many years of age.  
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Haematologic progenitor cells for example, do have a hughe mitotic activity throughout life, as they 
have to repopulate the blood as differentiated blood cells reach the end of their lifespan or expand 
the population of circulating lymphocytes when confronted with new or known antigens. 
Circulating white blood cells represent easily accessible cells to measure the reflection of the aging 
process on the blood forming organs. They are quite particular as they are freely circulating and not 
fixed in a surrounding structure like other organs e.g. the breast gland, gastro-intestinal organs, and 
many others. 
In the breast, the functional glandular and ductal elements are embedded in fibrofatty tissue that 
forms the bulk of the mammary gland. The proportions of fat and collegenous stroma vary among 
individuals. The majority of cells that form the duct epithelium are columnar or cuboidal cells lining 
the lumen. Myoepithelial cells lie between the epithelial layer and the basal lamina. The normal 
periductal stroma contains fibroblasts, elastic and collageneous fibers, a scattering of lymphocytes 
(scarce in normal conditions), plasma cells, mast cells and histiocytes (Fig 4).  
 
 
 
 
Figure 4: Composition of the normal 
breast epithelium and stroma 
 
 
 
 
 
Senescence can occur in epithelial cells, fibroblasts or other cell types. High frequency of 
senescence in epithelial cells or fibroblasts of the tissue stroma will in the first place result in an 
aging phenotype of the affected organ.  
 
c. The senescence associated secretory profile 
 
In the first paragraph, we explained the role of senescence in aging and cancer prevention, and the 
trade-off that exists between both. 
The complexity of the interaction aging-cancer grows by the fact that senescence by itself can be 
stimulatory on the occurrence of cancer. This theory is called the theory of Antagonistic Pleiotropy. 
By natural selection, senescence is primarily a protection mechanism. Once the pressure of natural 
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selection declines (after the reproductive period), detrimental mechanisms are no longer eradicated 
as efficiently as before. This could be the explanation why senescence, protecting from cancer in 
younger age, seems to show cancer-promoting effects on the longer term.  
Cells that have activated the senescence program are arrested in cell cycle phase G0. As described 
previously, they acquire a specific phenotype with an enlarged flattened morphology, senescence 
associated β-galactosidase activity, reorganization of chromatin into foci of herterochromatin and 
resistance to apoptosis. But they keep an active metabolism, and acquire a Senescence Associated 
Secretory Phenotype (SASP)3,30. This SASP is composed of matrix remodeling enzymes, 
inflammatory mediators, angiogenic factors and growth factors, that are produced by the senescent 
cell itself, with the purpose to signal in a paracrine way it’s compromised status to the cells around. 
The purpose of the SASP is thought to be dual: retaining the permanent growth arrest, while 
attracting immune cells to the damaged cell in an attempt to destroy it. Nevertheless, it has been 
observed that meanwhile this SASP has harmful effects on the cells surrounding the cell of origin. 
As described in the previous paragraph, most organs or tissues in the body are not solely composed 
of a single cell type, but consist of epithelial cells and surrounding stroma (fibroblasts, endothelial 
cells, infiltrating immune cells, …) During aging, the probability that a senescent fibroblast and a 
premalignant (epithelial) cell (due to low grade DNA damage) come to lie in each other’s 
microenvironment, increases. It has been shown that these premalignant cells then lose 
differentiated properties, become invasive and undergo full malignant transformation3,31-33. Several 
preclinical experiments confirm this hypothesis: malignant epithelial cells that were injected 
together with senescent fibroblasts into xenografts, showed much more rapid growth compared to 
malignant epithelial cells alone32,34.  And even in non-malignant breast epithelial cells, senescent 
fibroblasts have been shown to disrupt the epithelial alveolar morphogenesis, the functional 
differentiation and the branching morphogenesis31. 
 
 
Figure 5: Taken from Krtolica et al 3, with permission from 
Elsevier. 
A model for synergy between mutations and cellular senescence in 
the occurrence of age-related cancer.  
 
 
 
The inflammatory microenvironment of the aging prostate has been suggested to be stimulatory on 
the proliferation of both epithelial cells and fibroblasts35, and older stromal prostate cells, when 
13 
 
cultured in vitro, were shown to exhibit stimulating effects on tumor formation by epithelial cell 
lines (benign and cancerous)36. 
 
The SASP is composed of several degrading enzymes and cytokines that modify the stroma such 
that is resembles an active stroma3,33,37,38. One of the most important components of the SASP has 
been suggested to be matrix metalloproteinase 3 (MMP3)31. This metalloproteinase has also been 
shown to promote mammary carcinogenesis39. The SASP of fibroblasts can be further composed of 
inflammatory cytokines and immune-modulatory chemokines (e.g. IL-6, IL-7, IL-8, MCP-2, MIP-
3a), shed surface molecules (e.g. ICAMs, uPAR, TNFreceptors), growth- and survival factors (e.g. 
GRO, HGF, IGFBP). It is not a fixed phenotype, but a fluctuating profile with broad overlap 
between cell types and growth conditions37,40,41. 
 
d. The autophagy to senescence transition 
 
An additive mechanism that has been proposed to explain the tumor promoting effects of a 
senescent microenvironment is “the autophagic tumor stroma model of cancer”42-45. This model 
states that fibroblasts, in transition to a senescent state, activate the autophagy process. It is 
therefore also called the Autophagy to Senescence transition (AST). The fibroblasts thereby shift 
towards an aerobic glycolysis-metabolism, creating high-energy mitochondrial fuels that feed the 
epithelial cancer cells. The discovery of the AST was driven by the finding that tumoral cells were 
capable to influence surrounding fibroblasts to undergo AST, by secreting hydrogen peroxide, 
which induced oxidative stress in the fibroblasts and resulted in activation of autophagy. This 
process was named “the Reverse Warburg Effect”. Fibroblasts displaying a constitutively activated 
autophagy program, turned out to show many morphological characteristics of senescence, as well 
as induction of p21(WAF1/CIP1). Moreover, they were shown to promote tumor growth and 
metastasis, when co-injected with human breast cancer cells42 which led to the hypothesis that AST 
is one of the mechanisms by which senescent stromal cells create a ‘fertile soil’ for the occurrence 
and progression of cancer.  
Typical genes associated with autophagy are BNIP3, CTSB or ATG16L142,46-48. Also, loss of CAV-
1 expression has been shown to be a biomarker for autophagy in stromal cells, and has been shown 
to correlate with a lethal tumor microenvironment49. 
 
2. Breast cancer in older patients  
a. Rising incidence and worse outcome 
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Epidemiological studies expect the number of individuals over the age of 65 years to double by the 
year 203050. Centenarians will be the fastest-growing subpopulation. In this population the 
association between cancer and aging is of particular interest. Approximately 60% of cancer 
incidence and 70% of cancer-related mortality occurs in individuals aged older than 65 years50. 
Breast cancer is a frequent disease in our community. In Europe, incidence for women 70 years or 
older diagnosed between 2000–04 varied from 100 to 350 per 100000 per year51. The most recent 
publically available data of the Belgian National Cancer Registry, show 10531 new breast cancer 
diagnoses in 2012, from which 3354 diagnoses are made in women of 70 years and older. The 
curves representing the age-standardized (using the World Standard Population) incidence of breast 
cancer, per age group, are shown below in figure 6..  
 
Figure 6: Age-standardized (using the World Standard Population) incidence of breast cancer in Belgium, by age 
group and incidence year. Source: Incidence Fact Sheets, Stichting Kankerregister, Incidentiejaar 2012, Brussel 
2015 
 
Breast cancer does not present as a uniform disease. Breast cancers differ in microscopic 
appearance and biologic behavior. The invasive breast carcinomas consist of several histologic 
subtypes, from which infiltrating ductal carcinoma represents the most frequent subtype. Other 
subtypes are invasive lobular, mixed ductal lobular, mucinous (colloid), tubular, medullary or 
papillary carcinomas. In most studies, the prevalence of tumors with more indolent features is 
higher in older compared with younger women. There are higher rates of hormone receptor 
expression52-55 (85 versus 70 percent in women ≥65 versus <50 years, respectively), lower rates of 
HER2 overexpression56,57, and a higher proportion of low-risk tumor histologies. As in younger 
women, infiltrating ductal carcinoma is the most common histologic type of breast cancer in the 
elderly population, however more indolent breast cancers (eg, mucinous and papillary carcinomas) 
are encountered more often with advancing age52,58,59. The incidence of hormone sensitive breast 
tumors differs mostly between very young patients and older patients, but there is less variation 
 8-Number of invasive tumours (N) and age-standardised incidence rate (WSR N/100,000) by age group and incidence year, Females
(Female Breast Cancer)
N WSR
Females 2004 2005 2006 2007 2008 2009 2010 2011 2012 2004 2005 2006 200 2008 2009 2010 2011 2012
All ages 9,387 9,381 9,488 9,659 9,572 9,606 9,916 10,534 10,531 109.5 106.9 107.5 107.6 104.6 103.8 106.3 111.1 108.3
    0-14 years 0 0 0 0 0 0 0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    15-39 ears 453 465 453 526 441 464 496 524 430 20.5 21.2 20.9 24.4 20.4 21.4 23.0 24.6 20.4
    40-49 years 1,674 1,730 1,726 1,728 1,714 1,638 1,639 1,673 1,649 217.1 220.9 218.7 217.6 214.9 205.1 205.2 208.8 206.5
    50-59 years 2,394 2,357 2,361 2,289 2,301 2,273 2,378 2,551 2,449 358.5 346.2 339.9 325.5 323.5 316.6 325.1 343.7 324.1
    60-69 years 2,184 1,997 2,098 2,164 2,145 2,232 2,337 2,505 2,649 427.0 389.9 407.6 409.8 395.3 403.5 414.4 431.9 440.6
    70+ years 2,682 2,832 2,850 2,952 2,971 2,999 3,066 3,281 3,354 342.2 353.4 358.4 362.3 363.0 363.1 371.5 394.6 398.1
N=Number of invasive tumours
WSR=Age-Standardised Rate, using the World Standard Population (N/100,000 person-years)
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between age groups among postmenopausal women60,61. A more recent way of classifying breast 
carcinomas is based on their gene expression profiles giving rise to different molecular subtypes. 
Luminal A and B, Her2-enriched, and ER negative (claudin-low and basal-like) subtypes exist.  
Luminal tumors are more often found in elderly patients, while Her2-enriched, basal-like and 
unclassified subtypes were more often found in young patients62,63.  
 
 
b. Lack of evidence based treatment choices 
 
Older patients are often diagnosed in a more advanced stage of the disease64, fear and hesitation to 
search medical attention probably explains this, at least in part. Most importantly, older patients are 
often withheld therapy, which worsens their prognosis65. This could be due because physicians fear 
to cause excessive toxicity by implementing similar treatments as is younger counterparts, or 
because they consider the treatment as futile. Whatever the reason may be, it shows the need to 
expand the evidence supporting treatment (or no treatment) decisions in this population. Only very 
few evidence-based guidelines exist in older patient groups, because in the past they were typically 
excluded from clinical trials. 
With the current progress that is made in oncology research and therapy development, and the 
expected increase in cancer in a growing older population, it is of utmost importance to be able to 
consider all treatment possibilities for these patients, and not just deny them therapy based on 
assumptions.  
 
3. The concept of frailty, biological age, and the heterogeneity of the patient population 
 
The difficulty in studying a ‘geriatric population’ with cancer, is it’s heterogeneity and 
multidimensionality. The definition of a geriatric patient is not only based on advanced age, but on 
a combination of age, medical problems or diseases, and limitations in several functional domains 
of the organism. Taking care of this population requires a holistic approach taking into account 
medical, functional and psychosocial aspects that can vary between patients. Cancer can arise in fit 
older patients as well as in very frail people, representing both ends of a spectrum. In other words, 
patients can be of the same calendar age, but their underlying biological age might be different.  
 
The syndrome of frailty has been extensively studied in geriatrics. It is not a simple synonym of 
disability or comorbidity, it represents a distinct biological process. Fried’s description of the frailty 
phenotype66 is often used: it is based on five pre-defined physical frailty criteria: unintentional 
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weight loss, self reported exhaustion, weakness/grip strength, slow walking speed and low physical 
activity.  
 
In extremely frail patients, a new diagnose of (breast) cancer often results in the decision to treat at 
most with endocrine therapy, which can be expected not to induce severe toxicity. These patients do 
often not present with the most difficult treatment decisions. More difficult are situations where the 
level of frailty of the patient is intermediate or where the patient is seemingly fit but very old. 
Especially in breast cancer, where the therapeutic possibilities are often various, and the cancer-
specific prognosis on average good. This is the reason why we chose this type of cancer as the 
model for our research.  
 
Aging of the entire body is reflected at different levels. First of all, it can be associated with clinical 
signs of aging, such as a decline in cognitive and physical performance.  
Secondly, aging can be measured in different biological systems by determining biological markers 
of aging. The blood is the most easily accessible organ to measure biological markers of aging (Fig 
7). 
 
 
 
Figure 7: Body aging: the aging process can be measured by clinical scoring systems or through measurement of 
biological markers 
 
 
a. The rising use of a (Comprehensive) Geriatric Assessment 
 
Oncologists have set up a society, specifically focusing on geriatric patients in oncology, with the 
purpose of developing more scientific evidence-based guidelines for treatment decisions in this 
heterogeneous population: SIOG, the International Society of Geriatric Oncology. SIOG strongly 
suggests to perform a geriatric assessment in all older patients diagnosed with cancer67-69.  
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A Comprehensive Geriatric Assessment (CGA), also called Geriatric Assessment (GA), is defined 
as a ‘multidimensional, interdisciplinary diagnostic process focusing on determining an older 
person’s medical, psychosocial and functional capability in order to develop a coordinated and 
integrated plan for treatment and long-term follow-up’70. The core components of a GA are social 
support, functional status, fatigue, comorbidity, cognition, mental health status, nutrition, and 
geriatric syndromes (e.g., dementia, delirium, falls, incontinence, osteoporosis or spontaneous 
fractures, neglect or abuse, failure to thrive, constipation, polypharmacy, pressure ulcers, and 
sarcopenia). In order to assess these domains, several standardized questionnaires are being used. 
An example of a comprehensive geriatric assessment that can be used (used by us in the Elderly 
Biomarker Study, cfr chapter 3), is shown in appendix 1.  
Ideally, all older cancer patients should be evaluated by CGA followed by interventions. But 
because geriatric assessment is a time-consuming activity, several screening tools have been 
developed to quickly assess all patients, and select patients that need a more in depth evaluation71. 
A screening tool is a brief assessment. They should be simple and quick. The purpose of this two-
step approach is to identify in a time-efficient way, which patients are in need of guided 
multidisciplinary interventions72. High sensitivity and negative predictive value are the most 
important characteristics. In addition, a high specificity is of interest in order to limit the number of 
unnecessary CGA’s. One of these screening tools, the G8, is included in appendix 1. Other 
examples are the VES-13 (Vulnerable Elderly Survey-13), TRST (Triage Risk Screening Tool), 
GFI (Groningen Frailty Indicator), TUG (Timed Up and Go). Many others exist. In a systematic 
review, G8 was described to be the most robust, but no specific screening tool can be recommended 
because performance of these tests can be situation-dependent71. 
 
b. Summarizing the CGA – Balducci 
 
The geriatric assessment serves in the first place as an in depth assessment73, to learn more about 
the sometimes hidden functional problems of patients. The result of the geriatric assessment should 
be taken into account when making oncological decisions. However, the multidimensional result 
makes interpretation of the ‘level of frailty’ that results from it, especially for oncologists with less 
geriatric experience, difficult. A certain quantification of the frailty level would make the 
implementation of the geriatric assessment into clinical decision-making easier. In medical 
oncology, we look for a definition of frailty capable to identify older subjects with a critical 
reduction in functional reserve, that makes them unsuitable for standard forms of cancer treatment, 
and mandates individualized treatment plans. 
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In general medicine, there are two main models known to define frailty: The Fried Criteria and the 
Cumulative Deficit Model. These models offer criteria and/or tests to classify patients into 
categories of fitness. They have however not been validated in an oncological population and do not 
always hold an answer for treatment decisions. For that reason, L. Balducci suggested a 
classification based on the results of geriatric assessment, which specifically classifies onco-
geriatric patients into the categories FIT – VULNERABLE – FRAIL74,75.  According to his 
publications, fit patients are patients that are functionally independent and without comorbidity, and 
who are candidates for any form of standard cancer treatment (with the possible exception of bone 
marrow transplant). Frail patients are only candidate for best supportive care, and vulnerable 
patients represent the category in between. They may benefit from some sort of pharmacological 
intervention but with personalized adaptations. 
Fit is hereby defined as age <85, no limitations in ADL or iADL, no (or mild) comorbidities and no 
geriatric syndromes. Frail is defined as age ≥ 85 years and/or dependence at ≥ 1 item of the ADL 
and/or ≥ 3 comorbid conditions and/or ≥1 geriatric syndrome (dementia, falls, delirium, depression, 
incontinence, osteoporosis, neglect and abuse, failure to thrive). Vulnerable patients are the ones in 
between, showing dependency at 1 or more iADL items, and/or with 1 or 2 severe comorbidities. 
 
Figure 8: The landscape of frailty evaluation. Green tests have been developed in oncological patients – yellow tests 
are being extrapolated from the general geriatric population to oncological patients 
 
The classification of Balducci represents an important attempt to make the geriatric assessment part 
of the oncological decision process. However, it represents a quite rough way of categorizing 
patients. Moreover, classifying patients above 85 years old, or patients with occasional incontinence 
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by default, as frail, holds again the risk to deny a useful treatment to the patients that could be fit 
enough to receive it.  
 
c. Biological markers of aging 
 
Besides the clinical measures of frailty, which reflect the clinically measurable consequences of the 
aging process, a lot of interesting research has been performed on the biological markers that are 
thought to reflect the underlying physiological process of biological aging and that might be useful 
in assessing a patients ability to tolerate cancer therapy. 
 
Telomeres 
A crucial role has been attributed to telomeres, in cells and tissues subjected to replicative aging. 
Telomeres are DNA–protein complexes of repetitive DNA sequences and telomere binding 
proteins76. They cap chromosomal ends in order to preserve chromosomal stability77. They are 
incompletely replicated in somatic cells and shorten with each cellular division until reaching a 
critical value. At that point, genomic instability occurs, and senescence mechanisms are activated78. 
Only germ cells and stem cells (and often also cancer cells) express telomerase, a reverse 
transcriptase that can re-elongate shortening telomeres again79. In somatic cells, there is no or little 
telomerase activity80. As a consequence, the number of cell divisions is limited (this is called the 
‘mitotic clock’ of a cell). Therefore, leukocyte telomere length (LTL) can serve as a marker of a 
cell's replicative “age”81, and, in extension, can mirror a person’s biological age82. In a population-
based cohort study with 3075 healthy, well-functioning men and women aged 70-79 years83 
leukocyte telomere length, although not associated with overall survival (HR 1.0; 95% CI 0.9-1.1) 
or death from any specific underlying cause including cancer, was positively associated with more 
years of healthy living. According to the authors, these findings suggest that although such crude 
assays of average telomere length may not yield strong biomarkers of survival in older individuals, 
they may be informative for healthy aging. LTL also correlates with several aging-related 
syndromes84 such as cardiovascular diseases85, heart failure86, osteoporosis87 and obesity88. 
It should be acknowledged that telomere length measurement techniques have intrinsic technical 
limitations, and that large inter-individual differences exist of which the biological meaning is not 
well known. Measurement of telomere length can be performed in different ways (mean telomere 
length by RT-qPCR or TRF, shortest telomere by FISH) each with their own advantages and 
disadvantages89. Although telomere biology is extremely interesting, the (prognostic/predictive) 
value of telomere length in an individual patient has not yet been established. This might be because 
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most often, average telomere length of all chromosomes is measured, whereas the shortest telomere 
length may be the crucial trigger for eg. replicative senescence, regardless of the overall value. 
 
Expression of p16INK4A in lymphocytes 
Lymphocyte senescence, and thus aging of the immune system, is reflected by increased mRNA 
expression of the cell cycle regulator p16INK4a 6.  As described before, the p16INK4a gene acts as an 
important regulator of senescence. It works as inhibitor of cyclin-dependent kinase 4/6. In healthy 
humans, p16INK4a expression in peripheral blood T lymphocytes increases markedly with physical 
inactivity and exposure to mutagens such as tobacco90. Also, T lymphocyte expression of p16INK4a 
increases exponentially with chronological age, with an average 10-fold increase between the ages 
of 20 and 8091. Although expression of p16INK4a in T-lymphocytes seems a very promising aging 
biomarker, the use of it is hampered by some technical challenges. It has to be determined on 
mRNA extracted from T-lymphocytes, which is not readily available in routine blood samples. As a 
solution, mRNA from total blood leukocytes can be used, although the correlation with age showed 
much less strong by using that approach. 
 
Inflammatory cytokines and immune regulating chemokines 
A role for inflammation in the process of aging and age-related disease has been clearly established 
in several large epidemiological studies of older adults. Although acute inflammatory responses are 
closely regulated in the elderly, a low-level elevation of inflammatory markers is commonly 
observed and is associated with several chronic conditions of aging such as physical and cognitive 
decline, cardiovascular diseases and diabetes, or cancer92. While antigen-directed/adaptive immune 
responses usually decline with aging, general/non-specific inflammation seem often to increase in 
the older patients, a phenomenon termed inflamm-aging93. Several reports have described an 
increase in pro-inflammatory cytokines (mainly interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor 
necrosis factor-alpha (TNF-α)), chemokines (Regulated on Activation, Normal T cell Expressed and 
Secreted (RANTES), and Monocyte Chemotactic Protein 1  (MCP-1)) and C-reactive protein 
(CRP), with increasing age even in healthy older people, while at the same time there is a decrease 
in anti-inflammatory mediators such as interleukin-10 (IL-10)92,94,95. 
The etiology of this rise in inflammatory status has not been entirely clarified. It is thought to be a 
result of several contributing factors such as cumulative oxidative damage that promotes 
inflammatory responses, declining levels of sex hormones after menopause and andropause92, 
increasing visceral adiposity, and chronic immune stimulation by persistent irritants especially 
latent viral infections, most particularly Cytomegalovirus96. It is not clear to what extent a systemic 
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repercussion of the local microenvironment changes induced by senescent cells contributes to this 
inflamm-aging, but a relationship has been suggested97.  
 
In community-dwelling elderly there is a clear association between IL-6 levels and functional 
disability98 and a “frailty” phenotype99. Interestingly, peripheral cytokine levels are often elevated 
prior to cognitive decline100, dementia101 and loss of physical performance102. Furthermore, markers 
of inflammation are considered as a predictive tool for mortality103,104.  
 
However, an important issue that limits the clinical use of inflammatory factors as potential aging 
biomarkers is the fact that their blood levels are dependent on inflammatory reactions caused by 
underlying health conditions. The timing of testing may therefore represent an important 
confounding factor, e.g. assessing inflammatory factors in patients post-operatively after cancer 
resection to judge longevity/fitness for adjuvant chemotherapy, might result in misleading 
conclusions because recent surgery itself most likely increases IL-6/CRP levels. Moreover, there is 
no clarity on the contributing factor of neoplasia in the rising inflammatory parameters, which 
might also be very variable according to the type of malignancy involved. 
 
Insulin/insulin-like growth factor 1 (IGF-1) metabolic pathway 
Numerous studies have shown that aging is hormonally influenced by an evolutionarily conserved 
insulin/IGF-1 signaling (IIS) pathway105. Caloric restriction has been proven to be successful in 
prolonging life span at least in rodents106. Levels of insulin-like growth factor 1 (IGF-1) have been 
shown to decline with advancing age107, but more interestingly, IGF-1 has also been mentioned as 
predictive for functional status. Associations with muscle strength, slow walking speed, and self-
reported difficulty with mobility tasks have been shown, as well as increased mortality with lower 
IGF-1108,109.  
 
Other potential biomarkers 
 
Several other potential biomarkers reflecting the aging process have been described. For example 
markers of telomere dysfunction110: cathelicidin-related antimicrobial peptide or CRAMP, stathmin, 
Elongation Factor - 1α  or EF-1α, and chitinase-3-like protein. These factors are secreted by bone 
marrow cells with short, dysfunctional telomeres, but not from cells with long telomere reserves. 
They can be detected in the serum/plasma of patients, and were found to be higher in older people, 
certainly in patients with comorbidities. Furthermore, changes in immune cell subsets and CMV 
serology results, can be compiled into an immune risk profile (IRP) comprising an inverted 
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CD4:CD8 ratio, accumulation of CD8+CD28- late-differentiated T cells, poor proliferative 
capacity, few B cells and CMV-seropositivity. This IRP has been shown to be associated with 
significantly increased 2-, 4- and 6-year mortality in very old people111,112 
 
All these biological markers have been described in association with the aging process, but none of 
them can be considered as the best biomarker of aging, and the value of these markers at the 
individual level has not yet been established. The most robust ones are leukocyte telomere length 
and IL-6, but probably all of them reflect a small part of the intrinsic aging process. 
 
4. Chemotherapy in Older patients 
 
Decisions on chemotherapy in older patients are difficult: oncologists should try not to deny therapy 
to patients fit enough to receive it, but they fear excessive and sometimes irreversible toxicity which 
is clearly more frequent in older patients compared to younger patients. Toxicity especially in older 
patients can present on the short-term: the well-known acute chemotherapy toxicity, but also on the 
longer term reflected by a progressive increase in frailty level, which could be related to an 
acceleration in the aging process caused by the treatment. For the short-term toxicity some 
parameters of the geriatric assessment are known to be predictive, these are summarized in the two 
scores that we further elaborate on in the next paragraph. This is the reason why a thorough 
assessment of a patient’s frailty level is advised before taking decisions on chemotherapy 
treatments. The value of aging biomarkers in refining these scores has never been tested.  
A few studies have made an attempt to investigate the effect of chemotherapy on the aging process 
by measuring some aging biomarkers, thereby trying to provide an explanation for longer-term 
toxicity. These studies are highlighted in the second paragraph. However, the findings are not 
uniform, and neither one of these studies has included clinical parameters to document if the 
changes in biomarkers do actually correspond to clinical changes.  
 
a. Prediction of short-term chemotherapy toxicity: CRASH score and Hurria Score 
 
Two studies have investigated the predictive value of geriatric assessment parameters for short-term 
chemotherapy toxicity  
The CRASH score developed by M. Extermann113 et al, uses simple parameters from routine clinic 
and geriatric assessment (diastolic blood pressure, instrumental activities of daily living (iADL), 
Lactate Dehydrogenase (LDH), ECOG performance status, Mini Mental State Examination 
(MMSE) and Mini Nutritional Assessment (MNA)) in combination with an assumption about the 
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intrinsic chemotherapy risk (called “Chemotox value”). This score stratifies patients into four risk 
categories (low, medium-low, medium-high and high) for developing hematological or non-
hematological toxicity after treatment with chemotherapy. Although this score, published in 2012, 
seems quite easily applicable into clinical practice, it has not gained a lot of popularity. One of the 
explanations might be that it involves an unknown chemotherapy-toxicity score (the Chemotox 
value) that oncologists are not familiar with. It is a score developed by the authors themselves, 
based on toxicity data of previous published trials that reflects the risk of toxicity for a given 
regimen, in a ‘standard’ patient.  
The predictive model developed by A. Hurria114 et al is more complex. It takes into account a lot of 
parameters (age, type of cancer, planned chemotherapy dosing, mono- versus polychemotherapy, 
hemoglobin (with different cut-offs for male and female), creatinine clearance, hearing impairment, 
number of falls in the last 6 months, help needed with taking medications, ability to walk 1 block, 
decreased social activities due to health (physical or emotional) problems). Based on these 
parameters, a total score can be calculated, ranging from 0 to 19, trichotomized into three categories 
with a different risk of treatment toxicity. This score as well, has not found entrance to the broad 
clinical practice, probably because of its complexity. 
Never has there been any study investigating the value of biological aging markers in predicting 
short-term chemotherapy toxicity. 
 
b. Prediction of long-term chemotherapy toxicity: influence of chemotherapy on the aging 
process 
 
Chemotherapy may influence the aging process via a variety of different mechanisms. Firstly, 
anticancer agents can induce cellular senescence through DNA damage115, either directly or 
indirectly via generation of free radical intermediates and inhibition of DNA repair enzymes. 
Secondly, chemotherapy may specifically accelerate telomere attrition in leukocytes, most likely 
due to direct telomere damage or possibly by inhibition of the enzyme telomerase116. Repeated 
cycles of intense haematological repopulation during chemotherapy may shorten telomeres more 
rapidly if telomerase is not compensating for endochromosomal DNA loss117-119. Such effects of 
anticancer drugs on the replicative capacity of blood cells may be more pronounced in older 
compared to younger patients120. Finally, neuroendocrine and immune functions can also be 
affected by chemotherapy and by corticosteroids that are often incorporated in chemotherapeutic 
regimens121. Chemotherapy might thus be expected to accelerate aging122 and this might be 
responsible for increasing frailty on the longer term after chemotherapy. There have already been 
some attempts to study this topic. 
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In vitro work on telomere length shortening in mesenchymal stem cells after chemotherapy 
treatment suggests a shortening effect of this treatment123. In 2002 Lee et al investigated leukocyte 
telomere length shortening in Non-Hodgkin lymphoma patients124. They followed up on 5 patients 
that received chemotherapy and measured leukocyte telomere length before and after the therapy. 
They found a decrease in mean telomere length when comparing the values before and after 
chemotherapy. In 2006, Unryn et al published a study on telomere shortening during 
chemoradiotherapy for Head and Neck Cancer120. Patients underwent blood sampling for 
measurement of leukocyte telomere length at diagnosis, during and after chemoradiotherapy. These 
blood samples showed a faster decrease in telomere length in patients receiving chemotherapy 
compared to historical controls (belonging to another research project). A third study investigated 
telomere dynamics in BRCA mutated breast cancer patients compared to other familial, or sporadic 
breast cancers. In the group of sporadic breast cancers they only found a transient decrease in 
telomere length that recovered to normal age-expected values after 2 years125. So they did not 
entirely replicate the findings of the two previous studies. Finally, in 2014 a study was published by 
Sanoff et al,126 not only investigating telomere length, but also several other aging markers before, 
during and after chemotherapy for breast cancer: p16INK4a expression and senescence-associated 
cytokines VEGFA, IL-6, IL-7, IL-8 and MCP-1. They found and increase in expression of p16INK4a, 
which might be compatible with an accelerated aging process, but did not find a decrease in 
leukocyte telomere length, thus refuting the findings of previous studies. VEGFA and MCP-1 were 
found increased after the chemotherapy treatment whereas the rest of the cytokines remained stable.  
 
Taken together, there are only a few studies investigating the effect of chemotherapy on the 
biological aging process, and these are of variable quality, as we will further elaborate on in the 
discussion of this thesis manuscript. Some of them suggest an increased rate of biological aging due 
to chemotherapy. But their findings are inconsistent with each other, and this together with the 
methodological shortcomings of these studies, makes the issue unresolved in our opinion. 
This is a difficult topic to study, as there is no readily available test to measure with certainty the 
biological age of a person. Most of the studies focused mainly on leukocyte telomere length, Sanoff 
et al also measured p16INK4A expression in T-lymphocytes, next to a few age-related cytokines. 
None of them included geriatric assessment on top of the biomarker results. 
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Objectives of the research 
 
The main objective of this doctoral research was to expand the scientific knowledge on the complex 
interface between cancer and biological aging. We chose the platform of breast cancer to do so, 
because of the high incidence of this disease, which will make our findings relevant for a broad 
population, as well as the different therapeutic options, making the prognosis of the disease fairly 
good even in older patients, provided that it is correctly treated. Moreover, most of the research 
work that we based our assumptions on has also been performed in breast cancer.  
 
As a first objective, we were interested to know if stromal characteristics would be different 
between breast cancers occurring in young patients, and breast cancers occurring in older patients. 
Based on the description of the SASP (senescence associated secretory profile) and AST 
(autophagy to senescence transition), and the hypothesis that senescent cells accumulate in the body 
with aging, tumors arising in older patients would be expected to display a stromal compartment 
with different characteristics. Senescence in the surrounding stroma is expected to result in a pro-
tumorigenic microenvironment with stimulation of proliferation, migration/invasion, and 
dedifferentiation. But never had this been shown in spontaneous occurring breast cancers. Most 
experiments that deal with the interaction between senescence and cancer start from fibroblast 
cultures, where senescence has been artificially induced.  The altered phenotype and functional 
activity of this type of fibroblasts are then shown to influence the behaviour and growth speed of 
(pre)malignant cells, in cell cultures as well as in xenografts. As a consequence of this approach, an 
overload of senescent or presenescent fibroblasts is present in these experiments. We don’t know if 
this reflects accurately the situation in spontaneous cancers. Accumulation of senescent cells with 
age has mostly been studied in fibroblasts localized in the skin16, but data on the frequency of 
senescent fibroblasts in the older breast are lacking. Moreover, controversy exists on whether we 
can extrapolate findings on in vitro senescence, to the situation in vivo.  
 
A second reason why we wanted to challenge the preclinical findings on this topic is the fact that 
they are difficult to reconcile with the experience in clinical practice. Cancers are more frequent at 
older age, but little evidence can be found for a more aggressive behavior of these tumor cells: 
breast cancers in older patients have on the contrary been shown to grow slower127 (in general), and 
to behave less aggressively, even when adjusting for different histological tumor characteristics128. 
 
We decided to study the biological aging process in the older human breast cancer 
microenvironment, and look for in vivo confirmation of key concepts such as senescence, DNA 
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Damage Response, SASP, and AST. For this purpose, we selected two groups of breast cancer 
patients, belonging to a young respectively old age category, and used Laser Capture 
Microdissection to separate stromal fields from the cancer cells.  
 
Next, we wanted to broaden our scope, and investigate the biological aging process in the rest of the 
host organism. We were interested to know how biological age can be accurately assessed in cancer 
patients, and if quantification of this aging process would allow us to refine treatment decisions in 
older breast cancer patients.   
 
As described in the introduction, a jungle of clinical and biological parameters exist that can reflect 
to a more or lesser extent the frailty level in older patients. Clinical evaluations are time consuming, 
the multidimensional result of these assessments might not always be easy to interpret for 
oncologists with less experience in the geriatric field, and not easy to implement into oncological 
decision making. Biological markers on the other hand, are highly variable, influenced by several 
confounding factors and the measurements are sometimes associated with technical challenges. In 
the field of gerontology, the association of aging and frailty with these markers has intensively been 
studied. Nevertheless, no single marker can yet be considered a validated biomarker of aging or 
frailty. Moreover, simple extrapolation of findings from a population without cancer, to the 
oncological setting has been debated: cancer lesions and the potential physiological changes that are 
caused by their presence might influence levels of these biomarkers. 
 
In a second chapter of this thesis, we therefore present a retrospective study, where we have been 
investigating the value of known biological markers, suggested to reflect aging and frailty, in an 
older breast cancer population. We also developed an alternative way of summarizing the result on 
GA, in order to obtain a single clinical score reflecting the ‘frailty level’. This LOFS (Leuven 
Oncogeriatric Frailty Score) could be easier to use in oncological decision-making compared to the 
full GA result, but on the other hand more sensitive for subtle changes in frailty than the currently 
known Balducci categories. 
 
In the third chapter of this thesis, we deal with a very important question for clinical practice: does 
chemotherapy treatment influence the biological aging process? We wanted to prospectively follow 
up on signs of aging (clinical by geriatric assessment, as well as biological by measuring 
biomarkers) in older patients receiving either or not chemotherapy for early breast cancer (without 
metastases). If chemotherapy would show to accelerate aging, this would be an important finding to 
take into account while deciding on indications for chemotherapy treatments. On the other hand, 
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absence of an aging-inducing effect might convince treating oncologists not to deny chemotherapy 
to fit patients that would derive significant benefit from it. We performed a prospective 
observational study following older breast cancer patients during and after chemotherapy, as well as 
a group of breast cancer patients not receiving chemotherapy. Besides the question if chemotherapy 
would accelerate biological aging, we investigated if frailty levels at diagnosis (assessed by geriatric 
assessment and biological markers) could be used to predict short-term chemotherapy toxicity or 
unplanned readmissions in hospital.  
 
  
28 
 
Results: Chapter 1: The footprint of the aging stroma in older breast cancer patients 
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ABSTRACT 
 
 
Introduction: Tumoral masses are not only composed of malignant cells, but also enclose a more 
or less ample stromal micromilieu, which has been shown to influence the cancer cell behaviour. As 
aging induces accumulation of senescent cells in the body, this micromilieu is thought to be 
different in cancers occurring in old patients compared to the younger counterparts. More 
specifically, senescence-related fibroblastic features, such as the Senescence Associated Secretory 
Profile (SASP) and the induction of Autophagy, are suspected to stimulate tumor growth and 
progression.  
Materials and Methods: We compared gene expression profiles in stromal fields of breast 
carcinomas by performing laser capture microdissection of the cancer-associated stroma from 8 old 
(≥80 years at diagnosis) and 9 young (< 45 years at diagnosis) triple negative breast cancer patients. 
Gene expression data were obtained by microarray analysis (Affymetrix). Differential gene 
expression and Gene Set Enrichment Analysis (GSEA) were performed. 
Results: Differential gene expression analysis showed higher growth-, dedifferentiation- and 
migration- promoting gene expression in the stromal samples of older vs younger patients. GSEA 
confirmed the presence of a SASP, as well as the presence of Autophagy in the the stroma of older 
patients. 
Conclusion: We provide the first evidence in humans that older age at diagnosis is associated with 
a different stromal micromilieu in breast cancers. The SASP and the presence of Autophagy appear 
to be important age-induced stromal features. 
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Introduction 
 
Oncology research over the past years has been focussing in the first place on tumor cell 
characteristics. However, tumoral masses are not exclusively composed of malignant cells, but also 
comprise a stromal component containing endothelial cells, (myo)fibroblasts, smooth muscle cells, 
adipocytes and inflammatory cells. Research on the stromal component of tumor masses has shown 
that stromal characteristics are correlated with disease outcome and behaviour1-10 in several 
malignancies. The stroma seems to play a very important role in tumor initiation, progression and 
metastatic spread11,12. The fibroblasts contained in this stromal compartment show a specific 
phenotype and are called ‘carcinoma-associated fibroblasts’ or CAFs13. As cellular senescence 
progressively occurs throughout lifetime in fibroblasts of various origins14, it seems plausible that 
the characteristics of the stromal compartment of breast cancers would differ between young and 
older patients. 
 
The incidence of breast cancer, the most frequent tumor occurring in women, increases with 
age15,16. Whereas breast cancer at young age usually reflects either a genetic defect or the impact of 
early life transforming effects on an immature breast epithelium, cancer in older patients is thought 
to arise from life-long exposure to harmful stimuli, such as DNA damaging agents, oxidative stress 
factors and telomeric loss. In addition, the microenvironmental changes caused by senescent cells 
might also be an important harmful trigger.  
 
Senescence in general is a protection mechanism that shuts down damaged cells17. Senescent cells 
are forced into a state of irreversible growth arrest18,19 and exhibit a specific phenotype 
characterized by enlarged size, flattened morphology, senescence-associated β-galactosidase 
activity, reorganization of chromatin into foci of heterochromatin and resistance to apoptosis20. 
They also acquire the so-called Senescence Associated Secretory Profile (SASP)21,22, maintaining 
the growth arrest and recruiting immune cells towards the damaged cells, in order to eradicate them. 
However, the SASP also seems to have a detrimental influence on nearby cells. Epithelial cells 
neighboured by senescent fibroblasts lose differentiated properties, become invasive and undergo 
full malignant transformation20,23-25. In this process, a major role has been attributed to the matrix 
metalloproteinase 3 (MMP3)23 together with other components of the SASP25,26, such as 
inflammatory cytokines and chemokines. This concept of senescence as useful cancer-protective 
mechanism in younger life but detrimental cancer-promoting mechanism in later life has been 
repeatedly described as an example of “antagonistic pleiotropy27,28” in cellular or animal 
models23,24,29-32. 
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An additional mechanism that has been proposed to explain the tumor-promoting effects of a 
senescent micro-environment is the “the autophagic tumor stroma model of cancer”33-36. This model 
states that fibroblasts, in transition to a senescent state, activate the autophagy process. During this 
so-called Autophagy to Senescence Transition (AST), the cells shift towards an aerobic glycolysis-
metabolism, creating high-energy mitochondrial fuels that feed the nearby epithelial cancer cells. 
Autophagic fibroblasts were shown to have tumor- and metastasis-promoting activity34. The 
discovery of this concept was preceded by the finding that tumoral cells can induce AST in 
surrounding fibroblasts, by secreting hydrogen peroxide that causes oxidative stress and activation 
of autophagy in the fibroblasts. This process was named “the Reverse Warburg Effect”, (as opposed 
to the original idea, called “the Warburg effect”, that aerobic glycolysis takes place in epithelial 
cancer cells). Fibroblasts displaying a constitutively activated autophagy program turned out to 
show many morphological characteristics of senescence, including induction of p21(WAF1/CIP1), 
which led to the hypothesis that AST is one of the mechanisms by which senescent stromal cells 
create a ‘fertile soil’ for the initiation and progression of cancer. 
 
Despite this knowledge, stromal differences with increasing patient age have so far never been 
investigated in vivo and little clinical evidence can be found for a more aggressive behavior of 
tumor cells growing in a context of ‘older’ stroma. On the contrary, breast cancers in older patients 
have in general been shown to grow more slowly and to behave less aggressively, even when 
adjusting for different histological tumor characteristics37. 
On these premises, we decided to compare the gene expression profile of tumor-adjacent stroma in 
older versus younger breast cancer patients paired for other clinico-pathologic parameters. 
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Materials and Methods 
Patient Selection and clinical specimens 
This study was approved by the Ethical Committee of the University Hospitals Leuven (Leuven, 
Belgium), in accordance with the International Conference on Harmonization Guidelines on Good 
Clinical Practice.  
Candidate patients were selected using the following criteria: 1)  < 45 years or ≥ than 80 years old; 
2) no neo-adjuvant chemotherapy treatment nor hormonal treatment before surgery; 3) surgery for 
early triple negative breast cancer (estrogen and progesterone <1%, and HER2 <2 by 
immunohistochemistry or FISH negative) and fresh-frozen resection specimens available (stored at 
-80°C at the Pathology Department of the University Hospitals Leuven); 4) no chronic 
inflammatory diseases to exclude confounding variables.  
From candidate patients, 1 section of the frozen tumor material was obtained for haematoxylin and 
eosin (H&E) staining. H&E sections were evaluated for tumoral and stromal content to localize the 
best areas for stromal microdissection (see Figure 1 as an example). Only tissue blocks consisting of 
invasive tumor with sufficient carcinoma-associated stromal fields to allow laser capture 
microdissection were selected. Tumors with >20% of infiltrating lymphocytes were excluded to 
prevent biases in the gene expression analyses.  
On the bases of the above criteria, 17 female breast cancer patients (9 young patients <45 years at 
diagnosis and 8 old patients ≥ 80 years at diagnosis) were eventually included in the study.  
 
Staining Procedures and Laser Capture Microdissection(LCM) 
Preparation of the Tissue Slides 
For the selected patients, 10 frozen sections of 10 µm thickness were mounted onto specific 
membrane slides (Steel frames with PET membrane from Leica, cat # 11505151) and were kept at -
80°C until the staining and dissection procedure was started. All tissue slides underwent LCM 
within 7 days after preparation.  
Staining 
Prior to LCM, tumor slides were stained with Cresyl Violet following a procedure optimized for 
maximizing RNA yield. Briefly, tumor slides were taken from -80°C and were fixed into a 95% 
ethanol solution for 30 seconds. Next, they were transferred to ethanol solutions with progressively 
decreasing concentrations (75%, 50%) for 30 seconds each. Then, Cresyl Violet dye (Cresyl Violet 
Acetate, pure, high purity biological stain from Acros, cat# AC229630050) at a concentration of 
0.2% was applied for 30 to 60 seconds, after which dehydration of the tissue was achieved by 
rinsing the slides with increasing concentrations of ethanol  (50%, 75%, 95%, 100%, 100%) for 15 
seconds each.  
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Laser Capture Microdissection 
After the staining procedure, LCM was accomplished within 30 minutes using a Leica laser 
microscope (Leica LMD6500). Dissected stromal pieces were immediately collected in an 
RNAse/DNAse-free capture vial, containing 25µl of stabilizing RNA extraction buffer. During 
dissection, care was taken to avoid blood vessels, zones containing infiltrating immune cells, or 
fatty tissue. Dissection was restricted to fields contained within the perimeter of the invasive tumor, 
or at the perimeter of the tumor, but in direct relationship with invasive epithelial nests. Pictures 
were taken before and after the dissection procedure (see Figure 2 as an example). After finishing 
dissection for 1 tumor slide, 25 microliters of RNA extraction buffer were added into the capture 
vial, and lysis was performed for 30 minutes at 42°C. The obtained lysate was stored at -80°C until 
further RNA extraction. 
For each patient, several tumor slides were laser dissected using this procedure (7 to 10 slides per 
patient according to size and amount of stromal fields within the tumoral tissue).  
 
RNA extraction and amplification  
RNA isolation was performed using the Arcturus Picopure RNA extraction kit (PicoPureTM RNA 
Isolation Kit, Arcturus, Cat # KIT0202/KIT0204) according to the manufacturer’s protocol. Briefly, 
lysates from the same patient/tumor were combined, and after addition of 50 µl of ethanol 70%, the 
pooled samples were passed onto pre-conditioned RNA extraction columns. After centrifugation 
and washing, DNAse was applied onto the column to eliminate residual DNA (RNase-Free DNase 
Set from QIAGEN, cat# 79254).  After washing, the purified RNA was eluted from the column 
using 11 µl of elution buffer. Samples were subsequently tested for RNA quality (RQI) on the 
ExperionTM (Bio-Rad) using high sensitivity RNA chips, and concentrations were measured using 
the NanoDrop 2000 spectrophotometer (Thermo Scientific). The quality of the RNA varied between 
samples, which is a known limitation of the laser capture microdissection procedure 38(see 
Supplementary Table 1). Prior to microarray analysis, RNA was pre-amplified using the Ovation 
PicoSL WTA System V2 (NuGEN, cat# 3312-24). The Ribo-SPIA technology implemented in this 
procedure is ideal for amplification of partially degraded and compromised RNA samples, 
contributes minimal coverage bias, and is highly reproducible39. The procedure is widely used in 
LCM projects and does not introduce significant bias into relative gene expression values40,41. A 
clean-up step using the Qiagen MinElute Reaction Cleanup Kit was also incorporated in the 
amplification procedure (Qiagen, cat#28204). After NuGEN pre-amplification of the RNA samples, 
RT-qPCR assessment of common housekeeping genes showed that the amplification procedure had 
resulted in highly concentrated cDNA fragments with sufficient size to be recognized by the 
primers (data not shown). 
35 
 
 
Gene expression analysis 
Gene expression was analysed using the Affymetrix HG-U133Plus2 microarray chips at the J-C 
Heuson Breast Cancer Translational Research Laboratory (Jules Bordet Institute, Brussels, 
Belgium) following the manufacturer’s instructions. Standard quality assessments were conducted 
on the resulting files, and all samples passed quality assurance for further analysis. Expression 
values were computed using the fRMA normalization method (fRMA Bioconductor package)42 
[PMID:20097884]. When multiple probe sets mapped to the same official gene symbol, we 
computed their average value.  
The expression data are available on the GEO repository. 
 
Statistical analysis 
Differential expression analysis 
To identify the genes that were differentially expressed in the two age categories (< 45 years vs ≥ 
80 years), we computed for each probe set the mean expression value in both age groups and 
calculated the fold change of these means, i.e., the ratio of the average expression of this particular 
gene in young compared to old patients. Genes with fold change larger than 1.5 or smaller than -1.5 
were considered as differentially expressed. 
In silico validation 
In order to validate the obtained differential gene expression data, gene expression data sets from 
other research projects that investigated laser dissected stromal samples obtained from breast cancer 
patients were retrieved. The datasets were available in NCBI Gene Expression Omnibus, under the 
following IDs: GEO:GSE5847; GEO:GSE4823; GEO:GSE14548.  
Gene Set enrichment analysis (GSEA) 
GSEA were conducted using our local reimplementation of the GSEA algorithm developed at the 
BROAD institute43. Briefly, genes were ranked according to their fold change in young versus old 
patients and an enrichment score (ES) ranging from -1 to 1  was computed. This score reflects to 
what extent the genes constituting a given reference class are enriched among the top up- or down-
regulated genes of the differential expression analysis. Low (negative) ES values correspond to an 
enrichment of the reference class among genes that are up-regulated in old patients while high 
(positive) ES values correspond to an enrichment of the reference class among genes that are up-
regulated in young patients. The FDR adjusted p-values associated with each ES value reflects the 
probability that an ES at least as high or as low could be obtained merely by chance. Adjusted p 
values <0.05 were considered as significant.  
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Results 
 
Patient Demographics 
For the purpose of the study, 17 female patients (9 young patients < 45 years at diagnosis, and 8 old 
patients ≥ 80 years at diagnosis) with available fresh-frozen breast cancer resection specimens and 
with sufficient stroma to allow laser-microdissection were selected. Extreme age categories were 
chosen in order to maximize the probability of detecting significant age-related differences. All 
patients underwent surgery for early breast cancer at the Multidisciplinary Breast Center (University 
Hospitals Leuven, Belgium) between 2000 and 2011. All patients had invasive ductal carcinomas of 
> 1.5 cm, and were negative for estrogen receptor, progesterone receptor and human epidermal 
growth factor receptor 2. Additional patient and tumor characteristics are summarized in Table 1.  
 
Differential Gene Expression Analysis 
A differential gene expression analysis using a 1.5 fold up- or downregulation as cut-off, revealed 
120 genes that were upregulated in older stromal samples and 107 genes that were downregulated in 
older stromal samples compared to younger (Table 2). Heatmaps constructed using the 25 top up- 
and downregulated genes, are shown in figure 3.  
 
Data validation 
As our sample size was small, we used publically available data sets in order to check the 
reproducibility of our findings. We found a significant overlap for 10 genes, of which 5 showed 
higher expression in older patients (p<0.01), and 5 genes showed a lower expression in older 
patients (p<0.01). 
The Venn Diagrams depicting the overlapping genes are shown in figure 4; gene details are listed in 
table 3. 
 
Gene Set enrichment analysis (GSEA) 
As a second analytical approach, we looked at the expression of predefined gene sets documented in 
the literature to be related to specific processes. A GSEA was carried out for these candidate genes.  
The resulting enrichment score (ES), which ranges from -1 to 1, reflects the enrichment in genes of 
a given reference class among the top up- or down-regulated genes from the individual gene 
ranking. Plots are shown in figures 5 and 6. Negative ES values correspond to an enrichment of the 
reference class among genes that are upregulated in old patients while positive ES values 
correspond to an enrichment of the reference class among genes that are upregulated in young 
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patients. The genes that have been included in each GSEA, with respective literature references, are 
listed in Table 4.  
 
Senescence genes  
In the individual gene expression analysis, no significant difference was found for CDKN1A, 
CDKN2A, TP53, GLB1 nor the retinoblastoma (RB) gene. Nevertheless, the enrichment analysis 
for this gene set resulted in an enrichment score of -0.53, suggesting enrichment of senescence 
genes in the stroma of older patients, although statistical significance was not reached (p=0.09) (Fig 
5B). The lack of significance might be due to the very small size of the reference classes. 
 
DNA Damage response  
None of the three most important components of the DNA damage response, ATM, NBN (=NBS1) 
and CHK2, were differentially expressed between young and old. Also, the obtained ES (0.57) for 
this gene set did not suggest upregulation in the older patients, and was not statistically significant 
(p=0.10) (Fig 5A). 
 
Senescence Associated Secretory Profile  
In the category of the genes involved in the Senescence Associated Secretory Profile, CXCL2 (fold 
change -1.59) and TNFRSF11B (fold change -2.11) were upregulated in the older patient samples, 
while CCL8 (fold change 1.61) showed downregulation in the older patient samples. The compiling 
GSEA analysis, though, confirmed a significant enrichment in SASP-related genes within the 
stroma of our older patient samples: ES -0.21; p=0.04 (Fig 6A). 
 
The reverse Warburg effect – Autophagy genes 
None of the genes described to be involved in the autophagy-senescence transition, showed a 
relevant difference in expression between young and old stroma at the individual gene level. 
However, when compiling them together in the GSEA analysis, we found a highly significant 
enrichment of autophagy genes in the older patient samples: ES -0.42; p<0.01 (Fig 6B).    
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Discussion 
 
The reason for the age-related increase in cancers has been debated for decades. Besides cumulative 
DNA damage throughout life, the accumulation of senescent cells is also assumed to create a tumor-
promoting microenvironment through the production of several cytokines, chemokines, and matrix 
remodeling enzymes (altogether called the SASP or Senescence Associated Secretory Profile). The 
SASP is held responsible for dedifferentiation, proliferation and increased migration/invasion of 
nearby (pre-)neoplastic cells23,24.  Moreover, the autophagy to senescence transition (AST), a key 
pathophysiological process that seems to take place in senescent stromal cells, is thought to enhance 
tumor growth by producing high-energy mitochondrial fuels that boost epithelial cancer cell 
proliferation33-35,44. 
  
So far, studies investigating the impact of stromal senescence on tumor development were usually 
based on in vitro fibroblast cultures, where senescence had been artificially induced. The altered 
phenotype and functional activity of such senescent fibroblasts have been shown to influence the 
behaviour and growth speed of (pre)malignant cells, in cell cultures as well as in xenografts. 
However, an overload of senescent or presenescent fibroblasts was present in these experiments, 
whereas solid data on the in vivo abundance of senescent fibroblasts in the older breast are lacking. 
In vivo senescence has mostly been studied in fibroblasts localized in the skin14. Furthermore, there 
is only limited clinical support for a more aggressive behaviour of breast cancers in older patients, 
even when correcting for histopathological characteristics37. This is in contradiction with the 
hypothesis that senescent stromal fibroblasts would promote tumor growth and invasion. We 
therefore wanted to investigate the molecular footprint of the older breast cancer microenvironment, 
in order to find in vivo confirmation of key concepts such as aging/senescence, DNA Damage 
Response, SASP, and AST. For this purpose, we selected two groups of patients belonging to 
extreme age categories, isolated cancer-associated stromal fields via LCM and investigated the gene 
expression profile.  
 
Differential gene expression analysis using a cut-off at 1.5 fold change in expression revealed 120 
upregulated and 107 downregulated genes in the stromal parts of older patients, compared to the 
younger ones. Validation of these findings on publically available stromal data, revealed a set of ten 
differentially expressed genes between young and old stromal samples. The young stromal samples 
mainly showed upregulation in genes that preclude migration and invasion by stabilizing the cells in 
the extracellular matrix, and stimulate differentiation (see Table 3 and Figure 4). RARRES 3 is a 
gene that regulates adhesion and differentiation of cells. In the context of tumoral cells, it has been 
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described as tumor suppressive45-47. RARRES3 has been described to have a suppressive effect on 
the development of metastases in colorectal cancer48 as well as in breast cancer45,49. It is positively 
correlated with tumor differentiation in colorectal cancer50, and downregulated at disease 
progression in B cell lymphocytic leukemias51. Likewise, SCUBE2 is a gene that inhibits breast 
cancer cell migration and invasion52,53. The clinicopathological correlations of SCUBE2 have been 
investigated in colorectal cancer, where expression of SCUBE2 was shown to correlate with a better 
outcome of the disease: Patients with SCUBE2‑positive tumors had a lower recurrence rate and 
better survival than patients with SCUBE2-negative tumors54. Also in breast cancer, Patients with 
positive SCUBE2 protein-expressing tumors have been shown to have better prognosis than those 
with negative SCUBE2 protein-expressing tumors in terms of disease-free survival55. A prognostic 
value of SCUBE2 in endometrial cancer has also been proposed: SCUBE2 expression was shown to 
be higher in grade 3 tumors versus grade 1 endometrial cancers. A positive correlation of SCUBE2 
expression with expression of hormone receptors (ER and PR) and PTEN was shown suggesting 
that SCUBE2 is a positive prognostic factor also in endometrial cancer56.  Upregulation of SFRP4, a 
component of the Wnt signalling pathway, improves adherence of cells to surrounding collagen and 
fibronectin, and thus results in less migration through the extracellular matrix57. SFRP4 has been 
shown to enhance sensitivity of cancer cells to chemotherapy58-60. It is the gatekeeper/inhibitor of 
Wnt signaling, and has been shown to decrease stem cell properties in cancer cells, to reverse 
epithelial to mesenchymal transition61,62 thereby leading to a less aggressive cell phenotype10 and a 
better outcome. COMP encodes a noncollagenous extracellular matrix protein. It is involved in the 
chondrogenic differentiation of mesenchymal stem cells.63,64 COMP has been studied in breast 
cancer cells, where high expression was correlated with shorter disease free survival and poor 
survival. In mice experiments, tumors expressing COMP were significantly larger and were more 
prone to metastasize as compared with control, mock-transfected, tumors. The authors found that 
COMP-expressing tumor cells appeared to undergo a metabolic switch, that is, a Warburg effect65. 
The molecular role of NAT1 is not very clear. Its major role seems metabolisation of xenobiotics. 
NAT1 expression has been studied in breast cancer where higher expression has been associated 
with better disease free and overall survival66 in women, but also with better overall survival in 
male breast cancer67. 
Taken together, it seems like the younger stromal compartment shows more signs of a stable 
extracellular matrix, where cells have a lower migrating capacity. Only for COMP, the 
compatibility with this hypothesis is less clear. An explanation could be that the outcome related to 
overexpression of a gene can differ according to the type of cell in which it is overexpressed: tumor 
cells versus stromal cells.  
40 
 
 
Significant upregulation in the older stromal microenvironment was shown for genes that are 
involved in proliferation, dedifferentiation and angiogenesis. ANXA3 has been associated with poor 
prognosis and increased proliferation rates in malignant disease. It is involved in the regulation of 
apoptosis, by affecting the Bcl-2/Bax-balance. Positive correlations with tumor size, axillary lymph 
node metastasis, and a worse overall survival in breast cancer have been reported68. When ANXA3 
is inhibited, cell proliferation is decreased68-70.  Elevated ANXA3 expression has also shown to be 
associated with tumor size, number of lesions, tumor stage, and poor prognosis in hepatocellular 
carcinoma71. A correlation with the development of colorectal adenocarcinoma has been 
suggested72. In renal cell carcinoma, the relationship seems opposite: downregulation of ANXA3 
was shown in renal cell cancers (versus non tumoral cells)73 although further distinction is made 
between expression of the long and short isoforms of the protein.  PROM1, also called CD133, is 
the second upregulated gene in the older patient samples. It is a transmembrane glycoprotein 
expressed by adult stem cells and thought to maintain stem cell properties by suppressing 
differentiation. It has mainly been described in tumors (hepatocellular carcinoma, melanoma), 
where it correlates with bad outcome measures such as advanced disease, more aggressive disease 
and metastatis 74-77. Also in small cell lung cancer, higher expression of PROM1 is linked to a worse 
prognosis (survival)78. In paediatric medulloblastoma, a significantly higher expression of PROM1 
was found both in patients with poorer prognosis as in those with metastasis. Kaplan-Meier analysis 
showed that both overall survival (OS) and progression-free survival (PFS) were shorter in patients 
with higher PROM1 mRNA levels than in patients with lower expression79. FGF13 plays a role in a 
variety of biological processes. It is a mitogenic, angiogenic80 and survival factor involved in cell 
migration and cell differentiation81. A high cytoplasmic staining of FGF13 was shown to be 
associated with a higher risk of biochemical recurrence (BCR) in prostate cancer, after radical 
prostatectomy82. High FGF13 expression was also suggested to mediate resistance of cancer cells to 
platinum based chemotherapy in cervical cancer cells83. TUBB2B was also upregulated in the older 
stromal samples, but its implication in the present context is less clear. The protein encoded by this 
gene is a major component of microtubules and has mainly been described in association with brain 
malformations84. In accordance with the mechanism of action of taxane-chemotherapy, the 
expression of TUBB2B has been described as a predictive marker of docetaxel activity85. A higher 
expression of TUBB2B in non-small cell lung cancer was associated with increased disease 
aggressiveness 86. In melanoma, microarray analysis showed that the β-tubulin gene group was 
significantly upregulated in a subpopulation with higher metastatic potential. TUBB2B which is a 
member of this group, exhibited significantly enhanced expression87. 
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Thus, these four genes, with upregulated expression in the older stromal samples, all seem to 
restrain differentiation and promote cell proliferation, invasiveness and metastasis, as opposed to 
the function of 4 of the 5 genes upregulated in young stromal samples. The fifth upregulated gene in 
the older stroma samples, WIF1, is a negative inhibitor of the Wnt(Wingless-type)/β-catenin 
signalling pathway. It is thought to inhibit proliferation, induce differentiation and cellular 
senescence by upregulation of tumor suppressor genes such as p53 or p2188,89. It is expressed by 
stem cells of the human interfollicular epidermis, and acts to suppress keratinocyte proliferation89. 
WIF1 protein expression in colorectal cancer has shown to be increased in cancer tissue versus 
normal tissue, and high expression of WIF1 showed to be associated with big tumor diameters and 
deep invasion90. On the contrary, WIF1 hypermethylation (i.e. silencing of the gene) was shown to 
be associated with an unfavorable prognosis in EGFR mutated lung adenocarcinoma patients91, and 
associated with ovarian cancers92 and cervical cancer93. While the proliferation-inhibiting and 
differentiation-inducing effects of this gene seem to be in contradiction with the proliferation- and 
metastasis-promoting activity of the other four upregulated genes in the older stromal samples, its 
senescence-inducing function may be an obvious explanation for the age-related stromal expression 
of WIF1 in our study.  
Taken together, we found evidence of a more tumor-favorable micro-environment in the stromal 
samples from older patients. 
 
As an additional analysis, we applied a candidate-gene approach by assembling sets of genes based 
on the literature. We specifically looked at the individual gene expression results for these genes, 
but also compiled them using a gene set enrichment strategy that reflects the representation of these 
genes among the top up- or down-regulated genes in old and young stroma samples. 
 
The molecular process of senescence is characterized by upregulation of several senescence genes. 
The most documented ones are TP53, CDKN2A (p16), CDKN1A (p21) and pRB94-96. 
These major senescence-inducing genes did not show significantly different expression values 
between young and old stroma in the individual gene analysis. Nevertheless, we observed in older 
patients an upregulation of PAI-1 (=SERPINE1, fold change -1.87), a matrix remodeling enzyme, 
which has also been described as a crucial regulator of aging and senescence by acting downstream 
of p53 and upstream of insulin-like growth factor binding protein-397. Furthermore, WIF1, 
described above as inhibitor of the Wnt/β-catenin signalling pathway and an inducer of senescence, 
was also increased in samples from old compared to young patients (fold change -2.10) (Table 2). 
These findings could be indicative of more widespread cellular senescence in our older stromal 
samples, compared to the young ones. Yet, as we have selected extreme age categories, we actually 
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had expected more pronounced differences in typical markers of cellular senescence like p16 or 
p53, which, however, remained unchanged. Gene enrichment analysis, based on 5 key senescence 
genes (see table 4) including the ones mentioned above, showed a tendency towards a more 
prominent senescence trait in older stroma, but no significant enrichment score was reached for this 
process in the older patient samples. Therefore we cannot decisively conclude that samples from the 
older patient group show increased senescence. 
 
The DNA damage response is a biological process that, upon severe DNA damage, triggers the 
switch towards a permanent growth arrest98. It was found that the molecular senescence program 
can only be induced when this DNA damage response has been activated for a sufficiently long 
time period21. 
We could not demonstrate any clear difference in the individual expression of 3 key players 
involved in the DNA damage response (ATM, NBN or CHEK2)98, nor did we find significant 
enrichment for this set of genes in the older patient samples.   
 
Coppé et al compared cell culture supernatants  from senescent versus non-senescent cell cultures26, 
and observed a marked overproduction and secretion of senescence-associated factors in the 
senescent cell cultures. The authors confirmed that these changes were due to upregulation of gene 
expression. In our stromal gene expression study, only a few of the SASP components described by 
Coppé et al.  showed significant age-related differential expression: CXCL2, a chemokine with 
immunoregulatory and inflammatory capacities, and osteoprotegerin (TNFRSF11B), a member of 
the TNF receptor superfamily showed overexpression in the old patient samples, while CCL8 
showed downregulation in the older versus the younger stromal samples. 
However, when compiling all the components of the SASP together in the gene enrichment 
analysis, we indeed confirmed a significant enrichment in SASP genes among genes upregulated in 
the older patient samples. SASP components are believed to act in a paracrine way, thereby 
influencing the surrounding cells. Premalignant cells, neighboured by senescent fibroblasts, lose 
differentiated properties, become invasive and undergo full malignant transformation20,23-25. 
Malignant breast epithelial cells, co-injected with senescent fibroblasts into xenografts, give rise to 
tumors much more rapidly compared to malignant cells alone24,29.  In non-malignant breast 
epithelial cells, senescent fibroblasts have been shown to disrupt the epithelial alveolar 
morphogenesis, the functional differentiation and the branching morphogenesis23. Also, the 
inflammatory microenvironment of the aging prostate has been suggested to stimulate the 
proliferation of both epithelial cells and fibroblasts30.  Furthermore, older stromal cells, when 
cultured in vitro, were shown to promote tumor formation from epithelial cell lines when co-
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injected in mice31. Here, we confirm for the first time the presence of the ‘SASP’ phenomenon in 
spontaneous, human breast cancers.  
 
Autophagy is assumed to precede or parallel the process of senescence33, as described by the term 
Autophagy to Senescence transition (AST). Typical markers for AST are loss of Caveolin-1 
(CAV1), upregulation of BNIP3, BNIP3L, Beclin-1, Cathepsine B, and ATG16L1.  
Our individual gene expression results did not show relevant upregulation of single autophagy-
related genes in the older stromal samples, but compilation of these genes into an enrichement 
analysis showed highly significant enrichment for autophagy genes in the older stromal samples. 
Thus, in addition to the presence of SASP, we also confirmed the presence of AST in the older 
stromal cancer milieu. As described above, AST promotes the production of high-energy 
metabolites, fueling the growth of nearby cancer cells.  
 
The fact that we confirm the presence of SASP and AST in older stromal samples provides in vivo 
support for the in vitro and xenograft evidence on these phenomena. This, however, does not solve 
the paradox between the stimulatory effect that these processes are supposed to have on proximate 
malignant cells, and the clinical finding that breast cancer in older patients rather behaves in a more 
indolent instead of a more aggressive way99.  Also, it remains puzzling that we find evidence for 
SASP and AST in older stromal samples, while we do not find convincing evidence for increased 
senescence in these samples. The small sample size, together with the low number of genes defining 
the ‘senescence’ program could partly explain the lack of significance for major senescence-related 
genes such as TP53, CDKN2A and pRB, both at the individual level and in the gene enrichment 
analysis. Further analysis like staining for Υ-H2AX foci could bring additional information on this 
question. 
 
Further in vivo work on this topic is certainly required. The technical challenge to dissect stroma 
from invasive tumor makes it difficult to study larger patient groups. However, in vivo confirmation 
of in vitro discoveries is indispensable to ensure constructive research efforts.  
 
Conclusion 
For the first time, we report on key pathophysiological concepts of cancer and aging, such as the 
Senescence Associated Secretory Profile, and the Autophagy to Senescence transition, in vivo in 
human cancer patients.  
Our data, obtained by laser microdissection of breast cancer stroma from tumors diagnosed in 
young and old patients, show a modest, but significant difference in gene expression in young 
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versus old stromal samples. The difference concerns mainly genes responsible for proliferation, 
differentiation and migration into the extracellular matrix.  
Moreover, gene enrichment analysis confirms the presence of a Senescence Associated Secretory 
Profile and Autophagy to Senescence transition in the older stromal compartments, which to date, 
had never been investigated in spontaneous human cancerous lesions. These remarkable findings 
justify further research to fully elucidate the role of the aging stroma in (breast) tumor development 
and progression. 
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Patient'ID' age'at'
diagnosis'
ER' PR' HER2' Tumor'Type' Tumor'
grade'
Maximum'
tumor'size'(cm)'
pT>stage' pN>stage'
6' 27' neg' neg' neg' ductal' 3' 2.3' 2' 0'
5' 30' neg' neg' neg' ductal' 3' 2.5' 2' 0'
7' 32' neg' neg' neg' ductal' 3' 2.2' 2' 0'
1' 33' neg' neg' neg' ductal' 3' 2.8' 2' 0'
3' 39' neg' neg' neg' ductal' 3' 3.0' 2' 0'
2' 43' neg' neg' neg' ductal' 3' 3.0' 2' 2a'
4' 44' neg' neg' neg' ductal' 3' 2.8' 2' 0'
8' 44' neg' neg' neg' ductal' 3' 3.5' 2' 0'
9' 44' neg' neg' neg' ductal' 3' 3.0' 2' 0'
12' 80' neg' neg' neg' ductal' 3' 4.0' 2' 0'
16' 82' neg' neg' neg' ductal' 3' 3.5' 2' 0'
17' 82' neg' neg' neg' ductal'' 3' 1.5' 1c' 0'
13' 82' neg' neg' neg' ductal'' 2' 3.0' 2' 3a'
15' 83' neg' neg' neg' ductal' 3' 3.8' 2' 1a'
10' 83' neg' neg' neg' ductal' 3' 3.2' 2' 0'
11' 86' neg' neg' neg' ductal' 3' 3.0' 2' 0'
14' 87' neg' neg' neg' ductal' 3' 2.0' 1c' 0'!Table!1!:!Patient!and!tumor!characteristics!(pT!and!pN!stands!for!pathological!T!and!N!stage!following!the!TNM!staging)!
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Gene Full	Name Fold	
Change 
SPP1	 secreted	phosphoprotein	1	 -4,79	
EPCAM	 epithelial	cell	adhesion	molecule	 -4,02	
IL8	 Interleukin	8	 -2,74	
NR4A2	 nuclear	receptor	subfamily	4,	group	A,	member	2	 -2,45	
RGS2	 regulator	of	G-protein	signaling	2,	24kDa	 -2,41	
TREM1	 triggering	receptor	expressed	on	myeloid	cells	1	 -2,36	
PROM1	 prominin	1	 -2,27	
SCG2	 secretogranin	II	 -2,22	
LPL	 lipoprotein	lipase	 -2,20	
SDC4	 syndecan	4	 -2,19	
SLC2A3	 solute	carrier	family	2	(facilitated	glucose	transporter),	member	3	 -2,13	
PFKFB3	 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase	3	 -2,11	
TNFRSF11B	 tumor	necrosis	factor	receptor	superfamily,	member	11b	 -2,11	
WIF1	 WNT	inhibitory	factor	1	 -2,10	
NAMPT	 nicotinamide	phosphoribosyltransferase	 -2,08	
ENPEP	 glutamyl	aminopeptidase	(aminopeptidase	A)	 -2,07	
ZNF331	 zinc	finger	protein	331	 -2,07	
ANXA3	 annexin	A3	 -2,06	
HAPLN1	 hyaluronan	and	proteoglycan	link	protein	1	 -2,05	
CSN3	 casein	kappa	 -2,05	
KRT23	 keratin	23	(histone	deacetylase	inducible)	 -2,05	
VEGFA	 vascular	endothelial	growth	factor	A	 -2,03	
STC1	 stanniocalcin	1	 -2,01	
EGLN3	 egl	nine	homolog	3	(C.	elegans)	 -1,97	
ADM	 adrenomedullin	 -1,96	
G0S2	 G0/G1switch	2	 -1,95	
BAMBI	 BMP	and	activin	membrane-bound	inhibitor	homolog	(Xenopus	
laevis)	
-1,93	
TDO2	 tryptophan	2,3-dioxygenase	 -1,93	
CD24	 CD24	molecule	 -1,92	
DNER	 delta/notch-like	EGF	repeat	containing	 -1,92	
IBSP	 integrin-binding	sialoprotein	 -1,91	
HSPA2	 heat	shock	70kDa	protein	2	 -1,90	
ERRFI1	 ERBB	receptor	feedback	inhibitor	1	 -1,89	
MUCL1	 mucin-like	1	 -1,89	
APOLD1	 apolipoprotein	L	domain	containing	1	 -1,89	
SHISA2	 shisa	homolog	2	(Xenopus	laevis)	 -1,88	
GPX3	 glutathione	peroxidase	3	(plasma)	 -1,87	
SERPINE1	 serpin	peptidase	inhibitor,	clade	E	(nexin,	plasminogen	activator	
inhibitor	type	1),	member	1	
-1,87	
COL2A1	 collagen,	type	II,	alpha	1	 -1,86	
CP	 ceruloplasmin	(ferroxidase)	 -1,85	
COL9A3	 collagen,	type	IX,	alpha	3	 -1,85	
ENO2	 enolase	2	(gamma,	neuronal)	 -1,84	
FOSB	 FBJ	murine	osteosarcoma	viral	oncogene	homolog	B	 -1,84	
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TSPAN13	 tetraspanin	13	 -1,82	
CYP4X1	 cytochrome	P450,	family	4,	subfamily	X,	polypeptide	1	 -1,82	
TFAP2C	 transcription	factor	AP-2	gamma	(activating	enhancer	binding	
protein	2	gamma)	
-1,81	
EGR3	 early	growth	response	3	 -1,81	
SOX11	 SRY	(sex	determining	region	Y)-box	11	 -1,79	
CLEC5A	 C-type	lectin	domain	family	5,	member	A	 -1,78	
CYP26B1	 cytochrome	P450,	family	26,	subfamily	B,	polypeptide	1	 -1,78	
SLPI	 secretory	leukocyte	peptidase	inhibitor	 -1,78	
PI15	 peptidase	inhibitor	15	 -1,78	
RBP7	 retinol	binding	protein	7,	cellular	 -1,77	
SERPINA3	 serpin	peptidase	inhibitor,	clade	A	(alpha-1	antiproteinase,	
antitrypsin),	member	3	
-1,77	
CCDC102B	 coiled-coil	domain	containing	102B	 -1,75	
MTHFD2	 methylenetetrahydrofolate	dehydrogenase	(NADP+	dependent)	2,	
methenyltetrahydrofolate	cyclohydrolase	
-1,74	
CFI	 complement	factor	I	 -1,74	
FCGBP	 Fc	fragment	of	IgG	binding	protein	 -1,73	
GPNMB	 glycoprotein	(transmembrane)	nmb	 -1,73	
FCGR2A	 Fc	fragment	of	IgG,	low	affinity	IIa,	receptor	(CD32)	 -1,72	
MAL2	 mal,	T-cell	differentiation	protein	2	 -1,72	
UAP1	 UDP-N-acteylglucosamine	pyrophosphorylase	1	 -1,71	
IER3	 immediate	early	response	3	 -1,70	
COL4A1	 collagen,	type	IV,	alpha	1	 -1,69	
EFNB2	 ephrin-B2	 -1,69	
FCGR2B	 Fc	fragment	of	IgG,	low	affinity	IIb,	receptor	(CD32)	 -1,69	
BTBD3	 BTB	(POZ)	domain	containing	3	 -1,68	
FGF13	 fibroblast	growth	factor	13	 -1,68	
GALNT3	 UDP-N-acetyl-alpha-D-galactosamine:polypeptide	N-
acetylgalactosaminyltransferase	3	(GalNAc-T3)	
-1,67	
INHBB	 inhibin,	beta	B	 -1,66	
MANSC1	 MANSC	domain	containing	1	 -1,65	
DSP	 desmoplakin	 -1,64	
CLDN8	 claudin	8	 -1,64	
TUBB2B	 tubulin,	beta	2B	 -1,64	
PODXL	 podocalyxin-like	 -1,63	
EHF	 ets	homologous	factor	 -1,63	
TIPARP	 TCDD-inducible	poly(ADP-ribose)	polymerase	 -1,63	
ANGPT2	 angiopoietin	2	 -1,62	
ADAMTS1	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	1	 -1,62	
GPR4	 G	protein-coupled	receptor	4	 -1,61	
DBH	 dopamine	beta-hydroxylase	(dopamine	beta-monooxygenase)	 -1,61	
GPR183	 G	protein-coupled	receptor	183	 -1,61	
TFAP2A	 transcription	factor	AP-2	alpha	(activating	enhancer	binding	
protein	2	alpha)	
-1,60	
SNORD89	 small	nucleolar	RNA,	C/D	box	89	 -1,60	
CXCL2	 chemokine	(C-X-C	motif)	ligand	2	 -1,60	
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CXADR	 coxsackie	virus	and	adenovirus	receptor	 -1,60	
TPRKB	 TP53RK	binding	protein	 -1,60	
ETS2	 v-ets	erythroblastosis	virus	E26	oncogene	homolog	2	(avian)	 -1,60	
RAPH1	 Ras	association	(RalGDS/AF-6)	and	pleckstrin	homology	domains	1	 -1,60	
ADGRF5	 adhesion	G	protein-coupled	receptor	F	 -1,60	
CA2	 carbonic	anhydrase	II	 -1,59	
LIPA	 lipase	A,	lysosomal	acid,	cholesterol	esterase	 -1,59	
PGM2	 phosphoglucomutase	2	 -1,59	
KRT19	 keratin	19	 -1,58	
MGAT5	 mannosyl	(alpha-1,6-)-glycoprotein	beta-1,6-N-acetyl-
glucosaminyltransferase	
-1,58	
NCF2	 neutrophil	cytosolic	factor	2	 -1,57	
RHOU	 ras	homolog	gene	family,	member	U	 -1,57	
ALCAM	 activated	leukocyte	cell	adhesion	molecule	 -1,57	
LRRN1	 leucine	rich	repeat	neuronal	1	 -1,57	
OLR1	 oxidized	low	density	lipoprotein	(lectin-like)	receptor	1	 -1,55	
SLC19A2	 solute	carrier	family	19	(thiamine	transporter),	member	2	 -1,55	
PRPS2	 phosphoribosyl	pyrophosphate	synthetase	2	 -1,55	
MEGF10	 multiple	EGF-like-domains	10	 -1,55	
CYYR1	 cysteine/tyrosine-rich	1	 -1,54	
PLVAP	 plasmalemma	vesicle	associated	protein	 -1,54	
TM4SF1	 transmembrane	4	L	six	family	member	1	 -1,54	
PDGFA	 platelet-derived	growth	factor	alpha	polypeptide	 -1,54	
YBX2	 Y	box	binding	protein	2	 -1,54	
ATP2B1	 ATPase,	Ca++	transporting,	plasma	membrane	1	 -1,54	
PCDHB2	 protocadherin	beta	2	 -1,54	
DNMT1	 DNA	(cytosine-5-)-methyltransferase	1	 -1,54	
S100A8	 S100	calcium	binding	protein	A8	 -1,53	
MAP2	 microtubule-associated	protein	2	 -1,53	
ARRDC4	 arrestin	domain	containing	4	 -1,52	
FAM83D	 family	with	sequence	similarity	83,	member	D	 -1,52	
LSR	 lipolysis	stimulated	lipoprotein	receptor	 -1,52	
STK26	 serine/threonine	protein	kinase	26		 -1,51	
MIR181A2HG	 MIR181A2	host	gene	(non-protein	coding)	 -1,51	
VWA8	 von	Willebrand	factor	A	domain	containing	8		 -1,51	
MEST	 mesoderm	specific	transcript	homolog	(mouse)	 -1,51	
ZNF835	 zinc	finger	protein	835	 1,51	
NAT1	 N-acetyltransferase	1	(arylamine	N-acetyltransferase)	 1,51	
EPSTI1	 epithelial	stromal	interaction	1	(breast)	 1,51	
LOC221946	 hypothetical	LOC221946	 1,51	
OAS1	 2',5'-oligoadenylate	synthetase	1,	40/46kDa	 1,52	
SELL	 selectin	L	 1,52	
COX6C	 cytochrome	c	oxidase	subunit	VIc	 1,52	
TRIM41	 tripartite	motif-containing	41	 1,52	
IFI27	 interferon,	alpha-inducible	protein	27	 1,52	
IGF1	 insulin-like	growth	factor	1	(somatomedin	C)	 1,52	
SCAMP1-AS1	 SCAMP1	antisense	RNA	1	 1,52	
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CD207	 CD207	molecule,	langerin	 1,52	
IFI35	 interferon-induced	protein	35	 1,52	
GGH	 gamma-glutamyl	hydrolase	(conjugase,	folylpolygammaglutamyl	
hydrolase)	
1,52	
NOX4	 NADPH	oxidase	4	 1,53	
CNTN3	 contactin	3	(plasmacytoma	associated)	 1,53	
CCL5	 chemokine	(C-C	motif)	ligand	5	 1,54	
GALNT1	 UDP-N-acetyl-alpha-D-galactosamine:polypeptide	N-
acetylgalactosaminyltransferase	1	(GalNAc-T1)	
1,54	
SPON1	 spondin	1,	extracellular	matrix	protein	 1,54	
SEMA3C	 sema	domain,	immunoglobulin	domain	(Ig),	short	basic	domain,	
secreted,	(semaphorin)	3C	
1,54	
DDX60L	 DEAD	(Asp-Glu-Ala-Asp)	box	polypeptide	60-like	 1,55	
TNFSF10	 tumor	necrosis	factor	(ligand)	superfamily,	member	10	 1,55	
CXCL14	 chemokine	(C-X-C	motif)	ligand	14	 1,55	
WISP2	 WNT1	inducible	signaling	pathway	protein	2	 1,55	
STAT1	 signal	transducer	and	activator	of	transcription	1,	91kDa	 1,55	
COMP	 cartilage	oligomeric	matrix	protein	 1,56	
IGLJ3	 immunoglobulin	lambda	joining	3	 1,56	
LRRC17	 leucine	rich	repeat	containing	17	 1,56	
IFI44	 interferon-induced	protein	44	 1,56	
ISG15	 ISG15	ubiquitin-like	modifier	 1,56	
FBLN2	 fibulin	2	 1,57	
SLC6A6	 solute	carrier	family	6	(neurotransmitter	transporter,	taurine),	
member	6	
1,57	
MX2	 myxovirus	(influenza	virus)	resistance	2	(mouse)	 1,57	
SH3D19	 SH3	domain	containing	19	 1,57	
TRBC1	 T	cell	receptor	beta	constant	1	 1,58	
SGCE	 sarcoglycan,	epsilon	 1,58	
IGHM	 immunoglobulin	heavy	constant	mu	 1,58	
DCBLD1	 discoidin,	CUB	and	LCCL	domain	containing	1	 1,59	
PPAPDC1A	 phosphatidic	acid	phosphatase	type	2	domain	containing	1A	 1,59	
BST2	 bone	marrow	stromal	cell	antigen	2	 1,59	
MFAP2	 microfibrillar-associated	protein	2	 1,60	
PDGFD	 platelet	derived	growth	factor	D	 1,60	
IGKC	 immunoglobulin	kappa	constant	 1,60	
CST1	 cystatin	SN	 1,61	
CCL8	 chemokine	(C-C	motif)	ligand	8	 1,61	
RASGRF2	 Ras	protein-specific	guanine	nucleotide-releasing	factor	2	 1,61	
MX1	 myxovirus	(influenza	virus)	resistance	1,	interferon-inducible	
protein	p78	(mouse)	
1,63	
PDGFRL	 platelet-derived	growth	factor	receptor-like	 1,63	
ALDH1L2	 aldehyde	dehydrogenase	1	family,	member	L2	 1,63	
FAM198B	 family	with	sequence	similarity	198,	member	B	 1,63	
MIR100HG	 mir-100-let-7a-2	cluster	host	gene		 1,64	
GAPT	 GRB2-binding	adaptor	protein,	transmembrane	 1,65	
SELM	 selenoprotein	M	 1,65	
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DSCAM-AS1	 DSCAM	antisense	RNA	1	 1,66	
STMN2	 stathmin-like	2	 1,69	
FBLN5	 fibulin	5	 1,70	
IFIT3	 interferon-induced	protein	with	tetratricopeptide	repeats	3	 1,70	
SFRP4	 secreted	frizzled-related	protein	4	 1,71	
ACKR4	 atypical	chemokine	receptor	4		 1,71	
CPNE2	 copine	II	 1,71	
PSMB9	 proteasome	(prosome,	macropain)	subunit,	beta	type,	9	(large	
multifunctional	peptidase	2)	
1,72	
ST6GAL2	 ST6	beta-galactosamide	alpha-2,6-sialyltranferase	2	 1,72	
NEXN	 nexilin	(F	actin	binding	protein)	 1,72	
CD52	 CD52	molecule	 1,72	
MFAP5	 microfibrillar	associated	protein	5	 1,73	
RARRES3	 retinoic	acid	receptor	responder	(tazarotene	induced)	3	 1,75	
GXYLT2	 glucoside	xylosyltransferase	2	 1,75	
HMCN1	 hemicentin	1	 1,76	
EFEMP1	 EGF-containing	fibulin-like	extracellular	matrix	protein	1	 1,78	
IL21R	 interleukin	21	receptor	 1,78	
C8orf4	 chromosome	8	open	reading	frame	4	 1,78	
LINC01503	 long	intergenic	non-protein	coding	RNA	1503	 1,78	
OLFML3	 olfactomedin-like	3	 1,79	
CILP	 cartilage	intermediate	layer	protein,	nucleotide	
pyrophosphohydrolase	
1,81	
MVB12A	 multivesicular	body	subunit	12A		 1,82	
SCUBE2	 signal	peptide,	CUB	domain,	EGF-like	2	 1,83	
WNT2	 wingless-type	MMTV	integration	site	family	member	2	 1,85	
APOL3	 apolipoprotein	L,	3	 1,87	
ADRA2A	 adrenergic,	alpha-2A-,	receptor	 1,89	
HIST1H3I	 histone	cluster	1,	H3i	 1,92	
SLC46A3	 solute	carrier	family	46,	member	3	 1,92	
ARHGAP28	 Rho	GTPase	activating	protein	28	 1,93	
KANK4	 KN	motif	and	ankyrin	repeat	domains	4	 1,93	
SDC1	 syndecan	1	 1,95	
CMPK2	 cytidine	monophosphate	(UMP-CMP)	kinase	2,	mitochondrial	 1,96	
IFI44L	 interferon-induced	protein	44-like	 1,97	
FMO1	 flavin	containing	monooxygenase	1	 1,98	
TMEM119	 transmembrane	protein	119	 1,99	
FNDC1	 fibronectin	type	III	domain	containing	1	 2,00	
ADAMDEC1	 ADAM-like,	decysin	1	 2,00	
TPSAB1	 tryptase	alpha/beta	1	 2,02	
CPA3	 carboxypeptidase	A3	(mast	cell)	 2,02	
MMP3	 matrix	metallopeptidase	3	(stromelysin	1,	progelatinase)	 2,05	
IFI6	 interferon,	alpha-inducible	protein	6	 2,06	
IFIT1	 interferon-induced	protein	with	tetratricopeptide	repeats	1	 2,06	
SFRP2	 secreted	frizzled-related	protein	2	 2,09	
TRIM6	 tripartite	motif-containing	6	 2,10	
TPSB2	 tryptase	beta	2	(gene/pseudogene)	 2,19	
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RSAD2	 radical	S-adenosyl	methionine	domain	containing	2	 2,28	
LOXL1	 lysyl	oxidase-like	1	 2,30	
OMD	 osteomodulin	 2,35	
IGJ	 immunoglobulin	J	polypeptide,	linker	protein	for	immunoglobulin	
alpha	and	mu	polypeptides	
2,44	
FCGR1A	 Fc	fragment	of	IgG,	high	affinity	Ia,	receptor	(CD64)	 2,47	
MATN3	 matrilin	3	 2,55	
IGLV@	 immunoglobulin	lambda	variable	cluster	 2,65	
OGN	 osteoglycin	 2,99	
EPYC	 epiphycan	 3,04	
 
Table 2 : Genes with >1.5	or	<	-1.5	fold	expression	and	respective	fold	changes.	Negative	values	for	fold	change	indicate	upregulation	in	older	patient	samples,	positive	values	indicate	upregulation	in	younger	patient	samples. 
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Gene Full Name Fold 
change 
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 1.75 
SFRP4 secreted frizzled-related protein 4 1.71 
SCUBE2 signal peptide, CUB domain, EGF-like 2 1.83 
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 1.51 
COMP cartilage oligomeric matrix protein 1.56 
ANXA3 annexin A3 -2.06 
PROM1 prominin 1 -2.27 
FGF13 fibroblast growth factor 13 -1.68 
TUBB2B tubulin, beta 2B -1.64 
WIF1 WNT inhibitory factor 1 -2.10 
 
Table 3: Significant up- or downregulated genes after validation in the external validation dataset 
(see Fig 4). Negative values for fold change indicate upregulation in old patient samples, positive 
values indicate upregulation in young patient samples. 
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Gene Group Involved Genes References 
Senescence 
Associated 
Secretory profile 
IL1A, IL6, IL6R, IL6ST, IL8, CXCL1, CXCL2, CXCL3, CSF2, IL7, 
ICAM1, TNFRSF11B, HGF, IGFBP4, CCL8, PLAUR, IGFBP2, 
CCL26, IL13, CCL20, ICAM3, PGF, TNFRSF1A, TNFRSF1B, 
CCL13, CCL16, TNFRSF10C, CCL2, FAS, ANG, IGFBP6, IL1B, 
(CCL3), TIMP2, IL11, OSM, LEP, AXL, KITLG, FGF7, IL15, FGF2, 
IGFBP1, MIF  
(17) 
(21 - 22) 
(26) 
Autophagy to 
Senescence 
Transition 
CAV1, CTSB, BNIP3, PRKAA1, PRKAA2, LAMP2, MAP1LC3B, 
ATG16L1, HIF1A, NFKB1, DRAM1, TP73, MAPK8, E2F1, STK11 
(33 - 36) 
(44) 
DNA Damage 
Response 
ATM, NBN, CHEK2 (21) 
(98) 
Cellular 
Senescence 
CDKN1A, CDKN2A, TP53, RB1, GLB1 (17 – 19) 
(94 - 96) 
 
Table 4: Groups of candidate genes related to a specific pathophysiological process, built to perform gene 
set enrichment analysis (GSEA), and their respective references. 
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Patient ID RNA concentration 
before amplification 
(ng/microliter) 
RQI RNA concentration after 
amplification 
(ng/microliter) 
1 $ 4,6 3,9 340,8 
2 $ 7,7 6,9 441,7 
3 $ 3,4 na 498,8 
4 $ 9,2 4,6 361,8 
5 $ 7,2 5 328,9 
6 $ 3,8 4,8 344,5 
7 $ 5,8 6,7 439,2 
8 $ 4,9 2,2 410,8 
9 $ 3,9 na 388,3 
10 δ 12,3 7,7 458,6 
11 δ 9,7 6 482,0 
12 δ 10,7 6,5 577,1 
13 δ 6,6 6,6 338,9 
14 δ 7,5 6,8 346,3 
15 δ 8,8 3,9 266,2 
16 δ 4,5 7,0 448,7 
17 δ 8,0 2,7 465,0 
    
$ patient belongs to the young patient group δ	patient	belongs	to	the	older	patient	group	na	:	not	available		Supplementary	Table	1	:	RNA	concentration	and	RQI	value	(RNA	Quality	Indicator)	before,	and	RNA	concentration	after	amplification 
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Results: Chapter 2: Biological aging and frailty markers in breast cancer patients 
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Results: Chapter 3: The impact of adjuvant chemotherapy in older breast cancer patients on clinical 
and biological aging parameters. 
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ABSTRACT
Purpose. This prospective observational study aimed to evaluate the impact of 
adjuvant chemotherapy on biological and clinical markers of aging and frailty.
Methods. Women ≥ 70 years old with early breast cancer were enrolled after 
surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group 
(CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant 
treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were evaluated at 
inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood samples were collected 
to measure leukocyte telomere length (LTL), levels of interleukin-6 (IL-6) and other 
circulating markers potentially informative for aging and frailty: Interleukin-10 (IL-
10), Tumor Necrosis Factor Alpha (TNF-α), Insulin-like Growth Factor 1 (IGF-1), 
Monocyte Chemotactic Protein 1 (MCP-1) and Regulated on Activation, Normal T cell 
Expressed and Secreted (RANTES).
Results. LTL decreased significantly but comparably in both groups, whereas IL-6 
was unchanged at T2. However, IL-10, TNF-α, IGF-1 and MCP-1 suggested a minor 
biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 in 
the CTG, but recovered at T2, while remaining stable in the CG. 
Conclusion. Chemotherapy (TC) is unlikely to amplify clinical aging or induce 
frailty at 1 year. Accordingly, there is no impact on the most established aging 
biomarkers (LTL, IL-6). 
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INTRODUCTION
The incidence of breast cancer, the most frequent 
tumor occurring in women, increases with age. While 
adequate treatment can improve outcome and survival in 
the elderly, concerns over side effects or the idea of futility 
result in a lower use of adjuvant chemotherapy in this 
patient population. This might be one of the reasons why 
cancer-related mortality is higher in older patients [1]. The 
high variability of individual health status constitutes a 
major challenge in offering optimal therapy to the elderly. 
A comprehensive geriatric assessment (GA), evaluating 
functional status, comorbidity, socio-economic condition, 
nutrition and polypharmacy, is therefore necessary, and 
has been recommended by the International Society 
of Geriatric Oncology (SIOG) [2]. Based on our own 
findings, biological markers of aging and frailty could add 
on to this clinical evaluation [3, 4]. 
In line with the complexity of the aging process, 
a huge variety of potential aging biomarkers has been 
described. A crucial role has been attributed to telomeres, 
in cells and tissues subjected to replicative aging. They 
are incompletely replicated in somatic cells and shorten 
with each cellular division. Therefore, leukocyte 
telomere length (LTL) can serve as a marker of a cell’s 
replicative “age” [5], and, in extension, can mirror a 
person’s biological age [6]. LTL correlates with several 
aging-related syndromes [7]. An increasing low-grade 
chronic inflammatory status, reflected by an altered 
plasma level of multiple inflammatory mediators [8-10], 
is another hallmark of aging. Levels of interleukin-6 (IL-
6) and tumor necrosis factor alpha (TNF-α) continuously 
rise with age, and have been associated with several 
aging-related syndromes [11-13]. Conversely, the anti-
inflammatory cytokine interleukin-10 (IL-10) tends to 
decrease in blood during aging [14] and age-related 
diseases [15]. Furthermore, several chemokines also 
change during aging [16-19] : Monocyte Chemotactic 
protein 1 (MCP-1) blood levels are higher in older people 
compared to younger individuals [20-22]. Regulated 
on Activation, Normal T cell Expressed and Secreted 
(RANTES), has shown to undergo age-related changes as 
well, although, results from the literature are not consistent 
[21, 22]. Additionally, perturbation of the insulin/insulin-
like growth factor 1 (IGF-1) metabolic pathway has been 
implicated in aging-related disease, and reduced longevity 
in both animal models [23-25] and humans [26, 27, 12]. 
Chemotherapy may influence the aging process 
via a variety of different mechanisms. Firstly, anticancer 
agents can induce cellular senescence through DNA 
damage [28], either directly or indirectly via generation 
of free radical intermediates and inhibition of DNA repair 
enzymes. Secondly, chemotherapy may specifically 
accelerate telomere attrition in leukocytes, most likely 
due to direct telomere damage or possibly by inhibition 
of the enzyme telomerase [29]. Repeated cycles of 
intense hematological repopulation during chemotherapy 
may shorten telomeres more rapidly if telomerase is not 
compensating for endochromosomal DNA loss [30-32]. 
Such effects of anticancer drugs on the replicative capacity 
of blood cells may be more pronounced in older compared 
to younger patients [33]. Finally, neuroendocrine and 
immune functions can also be affected by chemotherapy 
and by corticosteroids that are often incorporated in 
chemotherapeutic regimens [34]. Chemotherapy might 
thus be expected to accelerate aging [35, 36, 33, 37, 38]. It 
has been hypothesized that an increased rate of molecular 
aging might explain some of the delayed adverse events 
linked to chemotherapy [39]. However, long-term follow-
up data, on both clinical and biological repercussions of 
chemotherapeutic treatments, have never been reported 
To ensure optimal treatment decisions in older 
patients, it is of utmost importance to further elucidate the 
impact of chemotherapy on the aging process, not only 
biologically, but most particularly in terms of clinical 
repercussion. Here, we report a prospective study to assess 
the effect of chemotherapy on biological and clinical aging 
markers in older patients with breast cancer.
RESULTS
In total, 109 consecutive subjects were enrolled 
in the study: 57 in the chemotherapy group (CTG) and 
52 in the control group (CG). Almost all CTG patients 
completed their adjuvant chemotherapy. One patient 
stopped after the first cycle, one after the second cycle and 
two patients after the third cycle because of adverse events 
(allergy, severe infection and overall intolerance). Two 
other patients stopped after 1 cycle because of an allergic 
reaction, but resumed chemotherapy with a taxane-free, 
anthracyclin containing regimen. Baseline tumor and 
treatment characteristics are described in Table 1.
Results of the different biomarker assays at the 
3 time points (T0, inclusion; T1, at 3 months; T2, at 1 
year) and their evolution over time are shown in Table 2 
and Figure 1. In brief, LTL was similar in both cohorts 
at inclusion, and decreased to the same extent in both 
groups, indicating no difference in evolution in the two 
cohorts (test for interaction p=0.88). Also for RANTES, 
the evolution was similar in both groups. In contrast, 
the other 5 biomarkers remained stable in the CG while 
significantly changing in the CTG. IL-6 decreased at T1 
and returned to initial levels at T2; MCP-1 decreased at T1 
but increased above baseline value at T2; IGF-1 showed a 
similar initial decline at T1 but only slightly recovered at 
T2. On the other hand, IL-10 increased at T1 but decreased 
at T2 and TNF-α levels were increased at both T1 and T2. 
To determine if differences in baseline frailty between 
groups could have influenced these results, we repeated 
the time interaction analysis correcting for frailty at T0. 
This analysis showed similar results (Table 2).
For background on geriatric assessment and our 
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newly developed frailty score the ‘Leuven Oncogeriatric 
Frailty Score (LOFS)’, we refer to the section patients and 
methods and appendix 1. GA results at the 3 time points, 
and the differential evolution over time (with and without 
correction for frailty) are displayed in Table 3 and Figure 
2. A significant interaction test, pointing to a differential 
evolution in time between both groups, was found for 
LOFS, instrumental activities of daily living (iADL), 
Mini Nutritrional Assessment – short form (MNA-SF) and 
Global Quality of Life (Global QoL), while this test was 
not significant for Activities of Daily Living (ADL), Mini 
Mental Status Evaluation (MMSE), Geriatric Depression 
Scale - 15 (GDS-15) and Charlson Comorbidity Index 
(CCI). A marked decline in LOFS, iADL, MNA-SF and 
Global QoL was noted at T1 in the CTG but not CG. 
However, all significant differences noted at T1 in the CTG 
returned to normal at T2. No significant modifications of 
frailty level according to Balducci were found in either 
of the two groups: the odds ratio for being fit rather than 
vulnerable, or vulnerable rather than frail according to this 
index was 0.90 (95% CI 0.27-3.07) from T0 to T1 and 
0.63 (95% CI 0.21-1.90) from T0 to T2 in the CTG, and 
there was no difference with the CG (test for interaction 
p=0.63) (see Figure 2A). 
Within the CTG we explored the influence of 
baseline frailty on the time evolution of biological and 
clinical aging markers. Because the very small number 
of truly frail patients in this chemotherapy group, we 
chose to dichotomise the patients comparing fit patients 
to vulnerable+frail patients according to Balducci, and 
patients with LOFS ≥ 8 to patients with LOFS < 8). 
Except for LTL evolution, that showed a significant 
time interaction with frailty status (p=0.04 for Balducci 
dichotomization and p=0.01 for LOFS dichotomization), 
no differences in evolution according to frailty status at 
the start were seen for other biomarkers. As for the clinical 
aging parameters, the evolution over time according to 
baseline frailty status showed to be different for MNA and 
Global Health (significant time interaction with Balducci 
category; p=0.02 and p=0.01 respectively) and for GDS 
and Falls (significant time interaction with LOFS category; 
p=0.04 and p=0.01 respectively), but not for CCI, ADL, 
iADL and MMSE.
Correlations of baseline (T0) aging biomarkers 
with chronological age and LOFS are shown in Table 
4. LTL showed a significant correlation with LOFS but 
not with chronological age. Of all biomarkers, IL-6 was 
most strongly associated with both chronological age 
and LOFS: the higher IL-6, the higher chronological 
age and the lower the LOFS. TNFα showed a strong and 
highly significant positive correlation with chronological 
age. Associations with other aging biomarkers were not 
significant.
Adverse events occurring during the study 
period were recorded at 3 months and at one year, and 
are summarized in Table 5. As expected, toxicity was 
Table 1: Baseline patient and tumor characteristics
Chemo Group
(n = 57)
Control Group 
(n = 52)
Age
Median, years (range) 73.5 (70-80) 75.0 (70-90)
pT 
1 
2 
3 
4 
n (%)
11 ( 19)
37 ( 65)
6 (11)
3 (5)
n (%)
21 (40)
30 (58)
0 (0)
1 (2)
pN 
0 
1-3 
n (%)
18 (33)
36 (67)
n (%)
27 (53)
24 (47)
Breast cancer phenotype§
Basal like 
HER2 positive (ER negative) 
Luminal A 
Luminal B HER2 negative 
Luminal B HER2 positive 
n (%)
11 (19)
6 (10)
9 (16)
22 (39)
9 (16)
n (%)
0 (0)
0 (0)
35 (67)
16 (31)
1 (2)
Adjuvant therapy 
   TC chemotherapy 
   G-CSF primary prophylaxis 
   Trastuzumab 1 year 
   Endocrine therapy 
   Radiotherapy 
n (%)
56 (100)
48 (86)
15 (27)
40 (71) 
46 (82)
n (%)
0 (0)
0 (0)
0 (0)
52 (100)
32 (62)
Abbreviations : ER : Estrogen Receptor; TC : Docetaxel-Cyclophosphamide; G-CSF : Granulocyte-Colony Stimulating Factor
§: Breast cancer phenotype : see ref 47 in manuscript, Goldhirsh et al.
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markedly more frequent in the CTG, particularly during 
treatment (i.e. between T0 and T1). We also assessed 
whether any of the aging biomarkers could predict the 
occurrence of grade II-III-IV toxicity at 3 months in the 
CTG. Analyses were performed for toxicity parameters 
that occurred in at least 5 patients. None of the aging 
biomarkers at baseline (T0) predicted development of 
grade II or higher toxicity, and neither did the Balducci 
score or LOFS (data not shown). 
Unplanned readmissions occurred between 0 and 
3 months in 12 patients (22%) of the CTG (N=54) and 
3 patients (6%) of the CG (N=50). Between 3 and 12 
months, these numbers were 9 (18%) for the CTG and 
15 (32%) for the CG. However, none of the biomarkers 
at baseline (T0) nor Balducci or LOFS predicted an 
unplanned readmission during chemotherapy.
DISCUSSION
Geriatric oncology is a growing discipline. Older 
breast cancer patients have a higher cancer-specific 
mortality [1], probably because therapy is withheld on 
concerns over side effects. Is this fear justified and are 
these suspected side effects actually related to the aging 
process? Some studies seem to show an accelerating 
effect of chemotherapy on the aging process [33, 35, 
36, 38]. One could anticipate an increase in geriatric 
problems after chemotherapy. This could mislead the 
oncologist not to administer chemotherapy where it 
would otherwise have been indicated. However, data on 
this topic still remain disparate to date. DNA damage (and 
DNA damaging drugs) are suggested not necessarily to 
cause or accelerate aging [40], and no report exists that 
investigated alterations in aging biomarkers, attributed 
to chemotherapy, show an impact on clinical outcome. 
Therefore, we prospectively compared clinical and as well 
as potential biological aging markers in a cohort of older 
breast cancer patients given or not given chemotherapy 
after surgery. The patients were all >70 years of age, thus 
investigating a truly ‘older’ population. In those patients, 
geriatric assessment often reveals previously unknown 
age-related problems [2]. 
After 1 year of follow-up, we found that 
chemotherapy did not significantly influence established 
markers of clinical frailty. Our data only revealed a 
mild and transient decrease of global fitness status in 
older breast cancer patients undergoing chemotherapy: 
increased clinical frailty, as evidenced by a lower LOFS 
score, was noted in the CTG (but not CG) after 3 months 
of treatment, but the frailty status returned to baseline 
level after one year. Frailty status according to Balducci 
did not change during the time course of the study. Global 
QoL was also slightly decreased at 3 months in the CTG 
(but not the CG), but was also restored after 1 year. The 
temporary decrease in fitness and QoL is not unexpected, 
and can be explained by acute and subacute chemotherapy 
toxicity. However, our study has proven that overall, the 
TC regimen [41-43] (generally administered with primary 
G-CSF support) is well tolerated in older breast cancer 
patients. Apart from febrile neutropenia (13% grade III), 
we noticed few grade III, and even no grade IV side 
effects.
Abbreviations. SD: Standard Deviation; CI: Confidence Interval; LTL: Leukocyte Telomere Length; IL-6: Interleukin-6; IL-
10: Interleukin-10; TNF-alpha: Tumor Necrosis Factor Alpha; MCP-1: Monocyte Chemotactic Protein 1; RANTES: Regulated 
Upon Activation, Normal T cell Expressed and presumably Secreted; IGF-1: Insulin Like Growth Factor 1
p-values in italic font show results corrected for patient frailty level at baseline
Table 2: Aging biomarker results at baseline (T0), 3 months (T1), and 1 year (T2), and their differential evolution over 
time in Chemo and Control Groups
Chemo Group
(n=57)
Evolution Over 
Time
Chemo Group
Control Group
(n=52)
Evolution Over 
Time
Control Group
Differential 
Evolution Chemo 
and Control 
(TimeInteraction)
T0 T1 T2 T0ÆT1 T0ÆT2 T0 T1 T2 T0ÆT1 T0ÆT2
LTL N
   T/S mean +/- SD
45
0.7 +/- 0.2
46
0.7 +/- 0.3
49
0.6 +/- 0.2
p=0.05
p=0.05
p<0.01
p<0.01
41
0.7 +/-0.3
45
0.6 +/-0.15
44
0.6 +/-0.14
p=0.02
p=0.02
p<0.01
p<0.01
p=0.88
p=0.87
IL-6 N
   pg/mL mean +/- SD
56
3.2 +/- 3.7
55
2.3 +/- 3.7
51
4.5 +/- 9.2
p=0.02
p=0.02
p=0.27
p=0.26
52
7.0 +/-13.9
48
11.4 +/-38.5
46
5.6 +/-6.1
p=0.95
p=0.77
p=0.66
p=0.45
p<0.01
p<0.04
IL-10 N
   pg/mL mean +/- SD
51
0.3+/- 0.4
50
0.3 +/- 0.3
47
0.2 +/- 0.1
p=0.05
p=0.01
p<0.01
p<0.01
50
0.2 +/-0.2
47
0.2 +/-0.2
46
0.2 +/-0.1
p=0.92
p=0.96
p=0.28
p=0.23
p<0.01
p<0.01
TNF-alpha N
   pg/mL mean +/- SD
56
2.5 +/- 10.1
55
2.9 +/- 9.7
51
3.3 +/- 9.6
p<0.01
p<0.01
p<0.01
p<0.01
52
2.3 +/-3.1
48
2.5 +/-3.4
46
2.5 +/-3.1
p=0.71
p=0.71
p=0.08
p=0.06
p<0.01
p=0.01
MCP-1 N
   pg/mL mean +/- SD
55
143 +/- 70
55
110.7 +/- 70
51
183.2+/- 48
p<0.01
p<0.01
p<0.01
p<0.01
52
189 +/-78
48
219 +/-131
46
207 +/-108
p=0.14
p=0.16
p=0.34
p=0.29
p<0.01
p<0.01
Rantes N
   pg/mL mean +/- SD
55
59562+/- 46691
55
61411+/- 53735
51
51903+/- 47600
p=0.78
p=0.83
p=0.01
p=0.01
52
59004 +/-43436
48
53215 +/-46461
46
55421 +/-48231
p=0.03
p=0.03
p=0.03
p=0.03
p=0.29
p=0.28
IGF-1 N
   ng/mL mean +/- SD
55
79 +/- 26
54
67 +/- 26
51
70 +/- 24
p<0.01
p<0.01
p<0.01
p<0.01
51
76 +/-36
48
77 +/-27
46
74 +/-34
p=0.31
p=0.35
p=0.48
p=0.64
p<0.01
p<0.01
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Figure 1: Evolution over time of aging biomarker results in the Chemo and Control Groups. * Designates statistical 
significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the Chemo group (green asterisk) or the Control group (blue asterisk) 
A. Mean Leukocyte Telomere Length (+95% CI) by Time and Study Arm B. Mean IL-6 (+95% CI) by Time and Study Arm (based on log 
transformed data, UNIT pg/mL) C. Mean IL-10 (+95% CI) by Time and Study Arm (based on square root transformed data, UNIT pg/mL) 
D. Mean TNF-α (+95% CI) by Time and Study Arm (based on log transformed data, UNIT pg/mL) E. Mean IGF-1 (+95% CI) by Time and 
Study Arm (based on log transformed data, UNIT ng/mL) F. Mean MCP-1 by Time and Study Arm (based on log transformed data, UNIT 
pg/mL) G. Mean RANTES by Time and Study Arm (based on log transformed data, UNIT pg/mL).
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Table 4: Correlation of baseline aging biomarkers with chronological age and clinical aging (according to LOFS).
Chronological age (years) Clinical aging (LOFS)
Spearman
correlation p-value N
Spearman
correlation p-value N
Telomere length -0.11 0.32 86 -0.27 0.01 85
IL-6 0.32 <0.01 108 -0.21 0.03 106
IL-10 -0.03 0.78 101 -0.05 0.62 99
IGF-1 -0.01 0.33 106 -0.03 0.75 104
TNF-α 0.34 <0.01 108 -0.18 0.06 106
MCP-1/CCL-2 0.18 0.07 107 -0.14 0.16 105
RANTES/CCL-5 -0.01 0.88 107 0.16 0.10 105
Abbreviations. LOFS : Leuven Oncogeriatric Frailty Score; IL-6 : Interleukin-6; IL-10 : Interleukin-10; IGF-1 : Insulin Like 
Growth Factor-1; TNF-α : Tumor Necrosis Factor-α; MCP-1/CCL2 : Monocyte chemotactic protein-1/Chemokine (C-C motif) 
ligand 2; RANTES/CCL5 : Regulated Upon Activation, Normal T cell Expressed and presumably Secreted/ Chemokine (C-C 
motif) Ligand 5
Table 3: Geriatric assessment results at baseline (T0), 3 months (T1), and 1 year (T2), and their differential evolution 
over time in Chemo and Control Groups
Chemo Group
  
(n=57)
Evolution Over 
Time
Chemo Group
Control Group
(n=52)
Evolution Over Time 
Control Group
Differential Evolution
(Time Interaction)
T0 T1 T2 T0ÆT1 T0ÆT2 T0 T1 T2 T0ÆT1 T0ÆT2
Frailty(Balducci) N
Fit n (%)
Vulnerable n (%)
Frail n (%)
56
12 (21)
21 (35)
23 (41)
53
8 (15)
23 (43)
22 (42)
48
10 (21)
15 (31)
23 (48)
p=0.87 p=0.41
52
10 (19)
17 (33)
25 (48)
48
9 (19)
13 (27)
26 (54)
46
7 (15)
13 (28)
26 (57)
p=0.34 p=0.77 p=0.63α
LOFS N
Mean +/- SD
56
7.5 +/- 2
53
6.7 +/- 2
48
7.4 +/- 2 p<0.01 p=0.60
51
6.8 +/- 2
48
7.0 +/- 2
46
6.8 +/- 2 p=0.48 p=0.45 p<0.01
ADL N
Mean +/- SD
6§ n (%)
0-5 n (%)
56
5.5 +/- 1
33 (59)
23 (41)
56
5.4 +/- 1
35 (62)
21 (37)
51
5.5 +/- 1
30 (59)
21 (41)
p=0.88
p=0.88
p=0.96
p=0.99
52
5.1 +/- 1
29 (56)
23 (44)
48
5.0 +/- 1
23 (48)
25 (52)
46
5.0 +/- 1
21 (46)
25 (54)
p=0.94
p=0.85
p=0.57
p=0.47
p=0.77
p=0.76
IADL N
Mean +/- SD
8§ n (%)
0-7 n (%)
57
6.6 +/- 2
24 (42)
33 (58)
56
6.0 +/- 2
16 (29)
40 (71)
51
6.8 +/- 2
26 (51)
25 (49)
p<0.01
p=0.01
p=0.39
p=0.39
52
5.8 +/- 2
17 (33)
35 (67)
48
5.8 +/- 2
17 (35)
31 (65)
46
5.7 +/- 3
17 (37)
29 (63)
p=0.71
p=0.75
p=0.57
p=0.60
p<0.01
p=0.01
Previous falls N
   No n (%)
   Yes n (%)
57
44 (77)
13 (23)
N/A
50
34 (68)
16 (32)
N/A p=0.28p=0.25
52
28 (54)
24 (46)
N/A
46
29 (63)
17 (37)
N/A p=0.33p=0.37
p=0.15β
p=0.15 β
MMSE N
   Mean +/- SD
57
27.9 +/- 2
56
27.6 
+/- 3
51
27.9 +/- 3
p=0.22
p=0.19
p=0.94
p=0.96
52
27.9 +/- 2
48
27.8 +/- 3
46
27.9 +/- 4
p=0.34
p=0.31
p=0.40
p=0.41
p=0.77
p=0.78
GDS-15 N
   Mean +/- SD
   0-4§ n (%)
   5-15 n (%)
55
2.9 +/- 2
46 (84)
  9 (16)
56
3.1 +/- 2
43 (77)
13 (23)
50
3.1 +/- 3
38 (76)
12 (24)
p=0.31
p=0.23
p=0.50
p=0.51
46
2.8 +/- 2
35 (76)
11 (24)
47
3.5 +/- 3
32 (68)
15 (32)
45
3.1 +/- 3
35 (78)
10 (22)
p=0.23
p=0.25
p=0.40
p=0.40 p=0.98p=0.98
MNA-SF N
   Mean +/- SD
   ≥ 12§ n (%)
   < 11 n (%)
57
11.1 +/- 2
25 (44)
32 (56)
55
9.9 +/- 2
16 (29)
39 (71)
50
11.5 +/- 2
27 (54)
23 (46)
p<0.01
p<0.01
p=0.19
p=0.13
51
11.0 +/- 2
23 (45)
28 (55)
48
11.3 +/- 2
29 (60)
19 (40)
46
11.4 +/- 2
23 (50)
23 (50)
p=0.24
p=0.32
p=0.23
p=0.21
p<0.01
p<0.01
CCI N
   Mean +/- SD
   0§ n (%)
   1 n (%)
   >=2 n (%)
54
0.6 +/- 1
32 (59)
12 (22)
10 (19)
53
0.7 +/- 1
32 (60)
10 (19)
11 (21)
49
0.7 +/- 1
28 (57)
12 (25)
9 (18)
p=0.42
p=0.48
p=0.16
p=0.78
52
1.1 +/- 2
27 (52)
12 (23)
13 (25)
50
1.1 +/- 2
27 (54)
10 (20)
13 (26)
46
1.2 +/- 2
22 (48)
11 (24)
13 (28)
p=0.86
p=0.97
p=0.35
p=0.91
p=0.63θ
p=0.86 θ
G8 N
   Mean +/- SD
   >14 n (%)
   ≤ 14 n (%)
56
14.2 +/- 2
28 (50)
28 (50)
NA NA N/A N/A
52
13.7 +/- 2
22 (42)
30 (58)
NA NA N/A N/A N/A
Global QoL N
   Mean +/- SD
57
64.2 +/- 
17
56
58.5 +/- 
20
50
69.5 +/- 22
p=0.06
p=0.05
p=0.11
p=0.08
52
63.8 +/- 17
48
64.6 +/- 
20
46
63.6 +/- 23
p=0.83
p=0.83
p=0.73
p=0.96
p=0.02
p=0.03
Abbreviations. SD: Standard Deviation; CI: Confidence Interval; ADL: Activities of Daily Living; IADL: Instrumental 
Activities of Daily Living; MMSE: Mini Mental State Examination; GDS: Geriatric Depression Scale; MNA-SF: Mini 
Nutritional Assessment-Short Form; MNA: Mini Nutritional Assessment
§: Maximum score, no abnormalities
α: calculation based on probability of being fit or vulnerable by time and study arm 
β: calculation based on probability of falling by time and study arm 
θ: calculation based on probability of having the lowest score at CCI, by time and study arm 
p-values in italic font show results corrected for patient frailty level at baseline
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Figure 2: Evolution over time of geriatric assessment parameters in the Chemo and Control Groups. * Designates 
statistical significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the Chemo group (green asterisk) or the Control group 
(blue asterisk) A. Predicted probability (+95% CI) of being ‘fit or vulnerable’ by Time and Study arm, by Balducci B. Mean Leuven 
Oncogeriatric Frailty Score (LOFS) (+95% CI) by Time and Study arm C. Mean score for Activities of Daily Living (ADL) (+95% CI) by 
Time and Study arm D. Mean score for instrumental Activities of Daily Living (iADL) (+95% CI) by Time and Study arm E. Mean score 
for Mini Mental State Evaluation (MMSE) (+95% CI) by Time and Study arm F. Mean score for Mini Nutritional Assessment Short Form 
(MNA-SF) (+ 95% CI) by Time and Study arm G. Mean score for Geriatric Depression Scale (GDS) (+95% CI) by Time and Study arm 
H. Mean Global Quality of Life (+95% CI) by Time and Study arm
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The absence of a pronounced aging/frailty-inducing 
effect of chemotherapy was further corroborated by 
measurements of some of the principal well-established 
aging biomarkers, such as LTL and IL-6. LTL was 
comparable in both groups at baseline and progressively 
decreased over the 1-year time course of the study with 
no significant difference between the two groups. This 
is in line with the well-known age-related process of 
progressive telomere attrition [6, 7, 44] but does not 
support the hypothesis that the aging process is accelerated 
by chemotherapy. Similar to LTL, the plasma marker 
IL-6 [13] did not reveal chemotherapy-induced aging 
progression when considering the evolution over the 
1-year study period. On the other hand, several of the 
additional plasma biomarkers that have previously been 
associated with aging [13, 15, 21, 22, 25, 27, 45-47], did 
suggest a slight aging-promoting effect of chemotherapy: 
decreases in IL-10 and IGF-1 and increases in TNFα and 
MCP-1 from baseline to 1 year were significantly more 
pronounced in the CTG compared to the CG, suggesting 
accelerated  biological aging. However, we tend to 
consider the clinical impact of alterations in only a few 
biomarkers that contribute to the so-called ‘inflammaging’ 
phenomenon rather minimal, especially as more robust 
aging biomarkers do not appear to show the same trend. 
Although geriatric assessment parameters and the 
patient’s perception of QoL did not change significantly 
at 1 year, one might argue that clinical changes may 
not immediately become visible, but might remain 
subclinical for a longer period of time. On the other hand, 
it was shown by Benitez-Beluga et al. [37] that biological 
changes induced by chemotherapy can recover to normal 
after a sufficiently long period of follow-up. Therefore, 
the transient changes observed shortly after treatment 
in our study, seem not very likely to have any clinical 
significance on the long term.
Of all evaluated biomarkers, IL-6 showed the 
strongest correlation with chronological age and LOFS, 
confirming its robustness as an aging biomarker as 
previously described [13]. Associations of the other aging 
biomarkers were less prominent and mostly not significant. 
It should be noted, though, that the cohort examined in this 
study only comprised elderly people within narrow age 
range (70 – 90 years). Hence, the lack of association with 
chronological age in this study does not necessarily imply 
that these markers are not age-related at all. 
From the clinical perspective, aging biomarkers 
that would be predictive for chemotherapy-associated 
adverse events (toxicity, unplanned readmissions), would 
be highly relevant. However, we found that none of the 
biomarkers tested was associated with grade II-III-IV 
toxicity or unplanned readmissions, and neither were the 
Table 5: Cumulative toxicity
Cumulative adverse event Chemotherapy Group /Control groupGrade in %
1 2 3 4
Febrile neutropenia T0 → T1 0 / 0 0 / 0 13 / 0 0 / 0
T1 → T2 0 / 0 0 / 0 0 / 0 0 / 0
Anemia T0 → T1 63 / 18 11 / 8 2 / 0 0 / 0
T1 → T2 18 / 25 2 / 4 0 / 0 0 / 0
Diarrhea T0 → T1 26 / 2 4 / 0 2 / 0 0 / 0
T1 → T2 2 / 0 2 / 0 0 / 0 0 / 0
Nausea/vomiting T0 → T1 41 / 2 7 / 0 0 / 0 0 / 0
T1 → T2 0 / 4 0 / 0 0 / 0 0 / 0
Anorexia T0 → T1 46 / 6 9 / 0 2 / 0 0 / 0
T1 → T2 6 / 2 6 / 4 0 / 0 0 / 0
Fatigue T0 → T1 44 / 26 22 / 0 2 / 2 0 / 0
T1 → T2 30 / 19 2 / 4 2 / 0 0 / 0
Pain T0 → T1 30 / 28 9 / 2 0 / 0 0 / 0
T1 → T2 40 / 53 4 / 2 0 / 0 0 / 0
Mucositis T0 → T1 24 / 0 2 / 0 2 / 0 0 / 0
T1 → T2 1 / 0 0 / 0 0 / 0 0 / 0
Sensory neuropathy T0 → T1 15 / 4 0 / 0 0 / 0 0 / 0
T1 → T2 8 / 0 0 / 0 0 / 2 0 / 0
Rash T0 → T1 17 / 0 0 / 0 0 / 0 0 / 0
T1 → T2 2 / 0 0 / 0 0 / 0 0 / 0
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clinical frailty scores (Balducci/LOFS) 
Due to the non-randomized design of the study, we 
cannot exclude some selection bias. The CG was in fact 
slightly less fit than the CTG at the start of the study, as 
apparent from LOFS and biomarkers at baseline and by 
long-term frequency of hospitalization events (between T1 
and T2). This was not unexpected, since not only patients 
at low risk for cancer recurrence, but also patients too frail 
for chemotherapy, were included as controls. However, 
this does not influence our conclusions, as we do not 
compare absolute values of test results at a specific time 
point, but rather consider differences in evolution over 
time of clinical and biological aging markers between the 
groups. 
Taken together, we conclude that chemotherapy, 
after 1 year, does not significantly influence clinical aging 
parameters, nor does it induce an altered evolution in the 
most robust aging biomarkers recognized to date (i.e. LTL 
and IL-6). Nevertheless, other aging biomarkers (MCP-1, 
TNF-α, IL-10 and IGF-1) evaluated in this study indicated 
a (mild) potential aging promoting effect of chemotherapy. 
We found, however, no evidence that changes in these 
circulating molecules, as a consequence of chemotherapy, 
do result in clinically relevant changes in frailty, in 
morbidity, or in higher (all-cause) mortality.
Our study is the first to report a prospective 
comparison of exclusively older breast cancer patients 
receiving or not receiving post-operative chemotherapy 
by measuring several different clinical (GA) and 
biological aging markers. The results demonstrate that 
although some biological markers do change during and 
after chemotherapy, there is no convincing evidence of 
a clinically relevant acceleration of the aging process. 
This is an important finding because it emphasizes that 
chemotherapy should not be denied to older breast cancer 
patients solely because of their advanced age.
PATIENTS AND METHODS
Patient population and clinical assessment
This prospective, multicentre, non-interventional 
study accrued patients in 2 academic and 3 regional 
hospitals in Belgium from 2009 until 2012 (www.
clinicaltrials.gov/ NCT00849758). Eligible patients for 
the chemotherapy group (CTG) were female, ≥70 years 
old with early invasive breast cancer for whom adjuvant 
chemotherapy was planned according to established risk 
factors and international guidelines [48]. The scheduled 
therapy consisted of docetaxel at a dose of 75 mg/m2 and 
cyclophosphamide at 600 mg/m2 every 3 weeks for a total 
of 4 cycles (TC scheme)[41-43]. Primary prophylaxis 
with G-CSF (granulocyte-colony stimulating factor) 
was administered as per standard practice guidelines. 
In parallel, we enrolled a control group (CG) consisting 
of early breast cancer patients ≥70 years old for whom 
chemotherapy was not indicated (or indicated, but 
judged not to be feasible), and who were administered 
an aromatase inhibitor as sole adjuvant systemic therapy. 
Patients either or not received adjuvant radiotherapy 
according to institution policy. In the chemotherapy group, 
patients with hormone sensitive tumors also received an 
endocrine therapy after completion of chemotherapy. 
Trastuzumab was associated to the adjuvant chemotherapy 
if the tumor was HER2 positive. 
The study was approved by the Ethical Committee 
of the participating hospitals and written informed consent 
was obtained from all patients.
Patients were enrolled after surgery. They underwent 
blood sampling, geriatric assessment (GA) and Quality of 
Life (QoL) evaluation at three time points. The first time 
point was between 3 and 6 weeks after surgery, and always 
before the first chemotherapy administration. The second 
time point was approximately 3 months after inclusion 
(day of last chemotherapy), and the last time point was 
around 1 year after inclusion.
We performed a G8 [49]_ENREF_44 screening 
test[49] at baseline, and a GA, at each time point. 
Social data (age, living situation, marital status and 
educational level) were assessed. Functional status was 
measured by Katz’s Activities of Daily Living (ADL) 
and by Lawton’s instrumental Activities of Daily Living 
(iADL) scales. A fall history (number of falls during the 
previous 12 months and presence of fall-related injury) 
was recorded. We determined cognitive status with the 
Mini Mental State Examination (MMSE) and mood with 
the 15-item Geriatric Depression Scale (GDS-15). The 
nutritional status was assessed using the Mini Nutritional 
Assessment-Short Form (MNA-SF). Polypathology 
and severity of medical problems were measured with 
the Charlson Comorbidity Index (CCI). Geriatric scales 
have been described in detail by Kenis C. et al [50]. 
GA results were categorized into “fit”, “vulnerable” and 
“frail” groups according to Balducci [51, 52]. However, 
as this categorisation has limitations (e.g. age above 
85 is always considered “frail”), we developed a new 
scoring system, the Leuven Oncogeriatric Frailty Score 
(LOFS), to summarize GA results in a more refined linear 
score ranging from 10 (very fit) to 0 (very frail). Details 
are described in appendix 1, and in one of our previous 
publications [4]. 
Classical oncological parameters such as Eastern 
Cooperative Oncology Group - Performance Status 
(ECOG-PS), tumor characteristics (i.e. tumor subtype 
according St-Gallen criteria [53] and TNM) and treatment 
details were recorded. Adverse Events according 
to CTCAE v4.0 and unplanned readmissions were 
recorded. An unplanned readmission was identified as 
a subsequent or repeat hospitalization, which could not 
have been foreseen at the time of baseline time point [54]. 
95 
 
  
Oncotarget10www.impactjournals.com/oncotarget
Polypharmacy was assessed by the number of different 
registered drugs (www.bcfi.be) the patient had been taking 
during the week preceding inclusion. QoL was assessed 
with the EORTC QLQ-C30 questionnaire, from which the 
last two questions (question 29 and 30) were further used 
to determine ‘global QoL’. 
Blood sampling and measurement of aging 
biomarkers
At each time point, blood was sampled in 4-mL 
EDTA K2E tubes for plasma isolation and leukocyte DNA 
extraction. 
Mean leukocyte telomere length (LTL) was 
measured on leukocyte DNA by qPCR [44] and plasma 
levels of IL-6, IL-10, IGF-1, TNF-α, MCP-1, and 
RANTES were assessed by ELISA. Detailed procedures 
are described in appendix 2.
Statistics and Endpoints
Statistics and endpoints are described in appendix 3.
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Figure 1. 
Evolution over time of aging biomarker results in the 
Chemo and Control Groups. 
*	Designates	sta+s+cal	signiﬁcant	(p≤	0.05)	diﬀerences	at	T1	or	T2,	compared	to	T0,	within	the	Chemo	group	(green	asterisk)	or	the	Control	
group	(blue	asterisk)	
A.  Mean	Leukocyte	Telomere	Length	(+95%	CI)	by	Time	and	Study	Arm	
B.  Mean	IL-6	(+95%	CI)	by	Time	and	Study	Arm	(based	on	log	transformed	data,	UNIT	pg/mL)	
C.  Mean	IL-10	(+95%	CI)	by	Time	and	Study	Arm	(based	on	square	root	transformed	data,	UNIT	pg/mL)	
D.  Mean	TNF-α	(+95%	CI)	by	Time	and	Study	Arm	(based	on	log	transformed	data,	UNIT	pg/mL)	
E.  Mean	IGF-1	(+95%	CI)	by	Time	and	Study	Arm	(based	on	log	transformed	data,	UNIT	ng/mL)	
F.  Mean	MCP-1	by	Time	and	Study	Arm	(based	on	log	transformed	data,	UNIT	pg/mL)	
G.  Mean	RANTES	by	Time	and	Study	Arm	(based	on	log	transformed	data,	UNIT	pg/mL)	
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Figure 1. 
Evolution over time of aging biomarker results in the Chemo and Control Groups. 
* Designates statistical significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the 
Chemo group (green asterisk) or the Control group (blue asterisk) 
A. Mean Leukocyte Telomere Length (+95% CI) by Time and Study Arm 
B. Mean IL-6 (+95% CI) by Time and Study Arm (based on log transformed data, UNIT 
pg/mL) 
C. Mean IL-10 (+95% CI) by Time and Study Arm (based on square root transformed data, 
UNIT pg/mL) 
D. Mean TNF-α (+95% CI) by Time and Study Arm (based on log transformed data, UNIT 
pg/mL) 
E. Mean IGF-1 (+95% CI) by Time and Study Arm (based on log transformed data, UNIT 
ng/mL) 
F. Mean MCP-1 by Time and Study Arm (based on log transformed data, UNIT pg/mL) 
G. Mean RANTES by Time and Study Arm (based on log transformed data, UNIT pg/mL) 
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Figure 2. 
Evolution over time of geriatric 
assessment parameters in the Chemo 
and Control Groups. 
*	Designates	sta+s+cal	signiﬁcant	(p≤	0.05)	diﬀerences	at	T1	or	T2,	compared	to	T0,	within	the	Chemo	group	(green	asterisk)	or	the	Control	group	(blue	asterisk)	
A.  Predicted	probability	(+95%	CI)	of	being	‘ﬁt	or	vulnerable’	by	Time	and	Study	arm,	by	Balducci	
B.  Mean	Leuven	Oncogeriatric	Frailty	Score	(LOFS)	(+95%	CI)	by	Time	and	Study	arm	
C.  Mean	score	for	Ac+vi+es	of	Daily	Living	(ADL)	(+95%	CI)	by	Time	and	Study	arm	
D.  Mean	score	for	instrumental	Ac+vi+es	of	Daily	Living	(iADL)	(+95%	CI)	by	Time	and	Study	arm	
E.  Mean	score	for	Mini	Mental	State	Evalua+on	(MMSE)	(+95%	CI)	by	Time	and	Study	arm	
F.  Mean	score	for	Mini	Nutri+onal	Assessment	Short	Form	(MNA-SF)	(+	95%	CI)	by	Time	and	Study	arm	
G.  Mean	score	for	Geriatric	Depression	Scale	(GDS)	(+95%	CI)	by	Time	and	Study	arm	
H.  Mean	Global	Quality	of	Life	(+95%	CI)	by	Time	and	Study	arm		
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Figure 2. 
Evolution over time of geriatric assessment parameters in the Chemo and Control Groups. 
* Designates statistical significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the 
Chemo group (green asterisk) or the Control group (blue asterisk) 
A. Predicted probability (+95% CI) of being ‘fit or vulnerable’ by Time and Study arm, by 
Balducci 
B. Mean Leuven Oncogeriatric Frailty Score (LOFS) (+95% CI) by Time and Study arm 
C. Mean score for Activities of Daily Living (ADL) (+95% CI) by Time and Study arm 
D. Mean score for instrumental Activities of Daily Living (iADL) (+95% CI) by Time and 
Study arm 
E. Mean score for Mini Mental State Evaluation (MMSE) (+95% CI) by Time and Study arm 
F. Mean score for Mini Nutritional Assessment Short Form (MNA-SF) (+ 95% CI) by Time 
and Study arm 
G. Mean score for Geriatric Depression Scale (GDS) (+95% CI) by Time and Study arm 
H. Mean Global Quality of Life (+95% CI) by Time and Study arm  
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Appendix 1 
Leuven Oncogeriatric Frailty Score (LOFS) 
 
LOFS%+2 LOFS%+1 LOFS%+0
ADL 6 5%.%4 ≤%3
iADL 8 7%.%4 ≤%3
MMSE 30%.%28 27%.%24 ≤%23
MNA.SF 14%.%12 11%.%8 ≤%7
CCI 0 1 ≥%2  
 
 
 
 
 
 
 
LOFS is a semi-continuous frailty score which integrates results from Activities of Daily Living 
(ADL), instrumental activities of daily living (iADL), Mini Mental State Examination (MMSE), 
Mini Nutritional Assessment (MNA-SF) and  Charlson Comorbidity Index (CCI).  The scoring 
range for each separate test is separated in three groups, the lowest part (worst score range for each 
particular test) resulting in a LOFS +0 (no contribution to the final 10-points score), the middle part 
in +1 (contribution of 1 point), and the highest part in +2 (contribution of 2 points). Subscores from 
the 5 tests are added up to result in a total score on a scale that ranges from 0 (poorest score; 
extreme frailty) to 10 (best score, fit patient). Individual results from the LOFS should be 
interpreted as a gradation of severity in the spectrum of frailty between the two extremes.  
  
FIT VULNERABLE 
0 
FRAIL 
10
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Appendix 2 : Methods 
Mean leukocyte telomere length (T/S ratio) 
Mean leukocyte telomere length was measured on DNA of leukocytes extracted from the  buffy coat remaining in the 4 
ml EDTA tube after plasma removal. Every DNA sample was first tested for DNA fragmentation by electrophoresis on 
a 1% agarose gel. Fragmented DNA samples were excluded from further analysis. Telomere Length was assessed by 
qPCR. According to this method, the relative amount of telomeric DNA (T/S ratio) is calculated based on the Cp values 
obtained for telomeric DNA (T) and for the single-copy housekeeping gene 36B4 (S), measured in the same sample. All 
samples were assayed twice in independent qPCR runs, each time in triplicate wells. Each run included a dilution series 
(i.e. 80, 20, 5 and 1.25 ng) of standard DNA (Human Genomic DNA, Roche cat. no. 11691112001). The T/S ratio for 
an experimental sample is the amount (ng) of standard DNA that matches the experimental sample for copy number of 
the telomere template (T), divided by the amount (ng) of standard DNA that matches the experimental sample for copy 
number of the single-copy gene (S).  Primer pairs used were 5’-
ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT-3’ and 5’-
TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA-3’ for telomeres and 5’-
CAGCAAGTGGGAAGGTGTAATCC-3’ and 5’-CCCATTCTATCATCAACGGGTACAA-3’ for  36B4. The reaction 
mixture  included 1x LightCycler 480 SYBR Green I Master, telomere primers at 0.6 µM each or 36B4 primers at 0.5 
µM each, and 20 ng of template DNA in a total volume of 20 µL. Plates were run on a Roche LightCycler 480 platform, 
using the following thermal cycling program : activation for 10 min at 95°C; two initiation cycles of 15s at 95°C 
followed by 15s at 49°C; 35 amplification cycles of 15s at 95°C, 10s at 60°C and 15s at 72°C. Melting curves were then 
established in order to check amplicon purity. 
Measurements of molecules in plasma 
Plasmatic levels of cytokines, chemokines and IGF-1 were analyzed by ELISA method following manufacturers’ 
instructions. 
IL-6 , IL-10, TNF-alfa, CCL5/RANTES, CCL2/MCP-1, and IGF-1 levels were measured with Quantikine ELISA kit 
(R&D Systems)  
Read-out was performed by dual spectrophotometric measurement: absorbance measured at 570 nm was subtracted 
from absorbance measured at 450 nm for IL-6, RANTES, MCP-1 and IGF-1. For TNF-alfa and IL-10, absorbance 
measured at 690 nm was substracted for absorbance measured at 490 nm.  All samples were assayed in duplicate. On 
each microplate, a standard curve, obtained from dilution of a standard with known concentration, was included.  From 
these standard curves concentrations of samples were calculated by a logistic curve-fitting algorithm.  
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Appendix 3 : Statistics and Endpoints 
 
Statistics  
For the primary endpoint, a linear model for longitudinal data was used with telomere length as response variable and 
time, study arm and their interaction as explanatory variables. An unstructured residual covariance matrix was modelled 
to account for clustering by repeated measures. For the secondary endpoints, linear models for longitudinal data were 
used for continuous responses, analogous to primary endpoint analysis. Analyses were performed on transformed 
responses where needed to improve symmetry of the distribution. Proportional odds models were used for ordinal 
responses, and logistic regression models for binary outcomes, both with random intercept to account for clustering by 
repeated measures. Spearman correlations were used for studying the association of aging markers with continuous 
variables. Kruskal-Wallis tests were performed to compare biomarker levels between more than 2 groups, and Mann-
Whitney U tests were used for comparisons between two groups. All tests are two sided, and a 5% significance level is 
considered for all tests. All analyses have been performed using SAS software, version 9.3 of the SAS System for 
Windows. Copyright © 2002 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are 
registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. 
 
Endpoints 
The primary endpoint was to assess whether adjuvant chemotherapy for breast cancer induces accelerated telomere 
attrition. As secondary endpoints, we examined the impact of chemotherapy on plasma levels of IL-6, IL-10, IGF-1, 
TNF-α, MCP-1, and RANTES, on GA parameters, clinical frailty scores (LOFS and Balducci) and on QoL. 
Additionally, we investigated correlations of biological aging markers at inclusion with chronological age and clinical 
frailty. 
Lastly, we investigated whether biological aging markers and clinical aging, at inclusion, were predictive for 
chemotherapy induced grade II-III-IV toxicity or unplanned readmissions. 
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Concluding Discussion and Perspectives 
 
1. Contribution of our work to the research field 
 
The main purpose of this doctoral thesis was to broaden the scientific evidence on cancer in older 
people, both on the molecular level (focusing on the complex relationship between the aging 
process and the occurrence and evolution of cancer cells), as well as on the clinical level where we 
tried to clarify on important questions that are encountered by oncologists treating older cancer 
patients. 
 
The aging breast cancer microenvironment 
 
Oncology research over the last years has been focusing primarily on the cancer cells themselves. 
However, the influence of the stromal milieu is gaining more attention and has been shown to play 
an important role in the behavior of the cancer cells. Based upon this knowledge, and the known 
phenomenon of cellular senescence, research groups have been investigating age-related changes in 
fibroblasts, and their suspected influence on cancer cells.  
Although the preclinical research on this topic has been showing very consistent findings, it is 
hampered by several important drawbacks that could have been introducing systematic bias in the 
results. First of all, most experiments start from fibroblasts in culture. Culture conditions are not in 
vivo conditions and could be influencing specifically some parameters of the senescence program 
(‘culture shock’ or ‘stress’ can induce senescence by itself). Secondly, by artificially inducing 
senescence in the cell cultures, these experiments have created an environment with an overload of 
senescent cells. This environment turned out in their results, to show cancer stimulatory effects. 
However, this model is probably overestimating the in vivo frequency of senescent cells. Especially 
as we do only have limited data available on how much senescent fibroblasts accumulate in the 
body during aging. Most clinical data also seem to suggest a less aggressive disease course in older 
breast cancer patients, which is difficult to reconcile with the suggested negative influences of an 
older microenvironment. 
 
Therefore, we felt that there was an urgent need to validate some key pathophysiological concepts 
on microenvironmental senescence, in the in vivo situation. We decided to design a study where 
fibroblasts were taken from a breast tumor without applying any further culture conditions, and to 
study the gene expression differences between very old, and very young breast cancer patients. The 
laser capture microdissection needed to perform this separation was a time-consuming procedure, 
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which explains the small sample size in the study. However, by validating our results on publically 
available datasets retrieved from other laser capture microdissection projects, we were able to 
confirm several of our findings, that most importantly, matched the hypothesis suggested in 
literature. We found a higher expression of genes responsible for proliferation, differentiation and 
migration in the stroma of older breast cancers. We found a higher expression of genes responsible 
for extracellular matrix stability in the younger breast cancer stroma. Although we only studied the 
mivroenvironment, and are therefore not entitled to make assumptions on the influence of this 
environment on the cancer cells, we can say that these results strongly suggest easier migration and 
invasion of cancer cells into the older microenvironment compared to the younger one.  
 
As a second step, we decided to use a candidate gene approach to investigate whether we could find 
evidence for the presence of a senescence associated secretory profile and for autophagy in the 
older breast cancer stroma. Both processes have been described as important pathophysiological 
changes related to senescence in the microenvironment and suggested to be the most important 
reason why an older microenvironment is cancer promoting. The fact that we could validate the 
presence of both processes in our breast cancer samples represents the first in-patient evidence that 
these phenomena take place in the microenvironment of spontaneous occurring breast cancers.  
 
Taken together, this is the first time that evidence for the presence of a senescence associated 
secretory profile and for autophagy in an older cancer microenvironment has been found in human 
cancer tissue. This is an important step in the further development of this research field.  
We must note that autophagy in the stroma is part of a two-way process: high-energy metabolites 
resulting from stromal autophagy fuel cancer cells, but cancer cells can also cause stromal 
autophagy by themselves, through oxidative stress by producing hydrogen peroxide. We can’t 
dissociate primary autophagy in the stroma as a result of senescence, from secondary autophagy 
caused by cancer cell influences. However, the fact that we find a significant enrichment in 
autophagy genes in the genes upregulated in older stromal samples shows that at least part of it 
must be explained by the difference in age. 
 
An unanswered question is why we do not find convincing evidence for senescence in itself (the 
gene enrichment result being unsignificant for these groups of genes) in the older stromal samples. 
It could be explained by the fact that we start from only a limited number of samples, and that we 
have used only a few, very typical senescence genes to construct the signature. The value of the 
enrichment score that was calculated for the process of senescence was negative, suggesting 
enrichment of the genes in the older samples. But it failed to reach significance. We must not forget 
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either, that aging is a multifactorial process, and that other organismal changes related to the aging 
process could compensate for the tumor promoting characteristics of the microenvironment.  
 
   Biological and clinical parameters of aging 
 
To answer our second an third research question, we performed a retrospective (Chapter 2) and a 
prospective study (Chapter 3), investigating the value of several biological markers in reflecting 
biological age, and subsequently using this information to interpret the influence of chemotherapy 
treatment on the older organism.  
 
The most important finding of the retrospective study was the fact that interleukin-6, an established 
frailty biomarker in geriatric medicine has been confirmed as an important frailty marker in cancer 
patients. This is not trivial, as cancer is known to induce inflammatory reactions in the body, which 
questioned the validity of inflammatory aging markers in oncogeriatrics.  Our study demonstrates 
that in the case of breast cancer these doubts are incorrect. Of course, we can’t exclude that the 
cytokine levels have been influenced by the presence of the neoplasm. Adding a third cohort of 
older women without breast cancer would have allowed dissecting this scientific question. However 
our investigational purpose was pragmatic and focused on studying the validity of potential aging 
biomarkers in oncogeriatric patients. For this reason, and also because of practical limitations, we 
did not include a cancer-free population. Moreover most breast cancers- especially when diagnosed 
in a non-metastatic state- don’t induce extreme cytokine responses. Our results prove that the 
changes induced by frailty overrule the smaller changes induced by the cancer itself. Results could 
be very different if the same study was repeated in tumors demosntrating important systemic 
repercussion, like for example metastatic small cell lung cancers. 
Furthermore, we demonstrated that other potential aging biomarkers, like leukocyte telomere 
length, MCP-1 and IGF-1 show correlations with calendar age, but in this study we did not show 
any relationship of these markers with frailty.   
In order to investigate the correlation of the biomarkers with clinical frailty, we used several 
approaches. We first of all used the internationally known classification of Balducci. As this is a 
simplified tool that ignores several nuances contained within the geriatric assessment, we tried to 
develop an alternative, more subtle method to summarize the level of frailty that results from a full 
geriatric assessment. We termed our new score LOFS, or Leuven Oncogeriatric Frailty Score. This 
score takes into account five of the crucial domains that are evaluated in a geriatric assessment: 
functional status for elementary daily activities (ADL) and for instrumental daily activities (iADL), 
cognition (MMSE), nutritional status (MNA-SF), and comorbidities (CCI), whereas the Balducci 
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categories do not include nutritional status, and do only include cognition from the start of dementia 
on (at the time it becomes a ‘geriatric syndrome’).   
An important missing piece in this research part is the lack of a gold standard. Ideally, we want to 
find a key marker that reflects biological age (better than does chronological age) and that is easy 
and quick to measure. This could be a single marker, or a compilation of biomarkers e.g. an ‘aging-
signature’. But we do not have a gold standard to compare our potential markers to. As a surrogate, 
we use frailty. As explained in the introduction, frailty has several definitions, and although it 
represents a syndrome on it’s own, it is also highly influenced by comorbidities. The only way to 
know if any biomarker (or a combination) does add on, or replaces the geriatric assessment in 
determining the biological age, would be to test it against end points like mortality or long term 
functional outcome. However, in a cancer population, where the cancer in itself can cause morbidity 
or mortality, these endpoints are again, biased. 
 
For this reason, we did not exclude the biomarkers that did not reflect frailty, from our analysis in 
the prospective study on chemotherapy and aging. This study was designed with as primary 
endpoint: does chemotherapy accelerate biological aging? From the previous, it is clear that 
biological age can be estimated with several biological and clinical parameters, but that no gold 
standard exists. At the time the study started, we chose leukocyte telomere length as primary 
parameter, as it was the aging marker that was best established in geriatric literature with less 
influence from inflammatory status. 
As answer to our primary question, we found that the leukocyte telomere length decreases over the 
follow up time of 1 year, but at the same pace in breast cancer patients receiving, or not receiving 
chemotherapy. We thus did not confirm previous reports mentioning a significant decrease in 
telomere length in patients treated with chemotherapy. We believe this is explained by several 
methodological shortcomings in previous studies, that we have tried to overcome in our own study.  
In the study of Lee et al124, telomere length was found to decrease in 5 patients receiving 
chemotherapy for Non-Hodgkin Lymphoma. However, not only was the number of patients very 
limited, these patients displayed a wide age range (19 years till 75 years old). They also received a 
variable number of chemotherapy cycles, and the chemotherapy scheme varied between patients.  
Moreover, the conclusion that decline in telomere length was due to therapy was made through 
comparison of the mean leukocyte telomere length in cancer patients after chemotherapy, with the 
mean leukocyte telomere length measured in an unrelated, healthy age-matched group at an 
arbitrary time-point. As telomere length is highly variable between patients, even of the same ages, 
comparison of absolute mean values between small patient groups of very different ages does not 
allow making sound conclusions. The next study on telomere length dynamics under chemotherapy, 
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was performed by Unryn et al120. They found faster telomere shortening in patients receiving 
chemoradiotherapy for head and neck cancer compared to historical controls. The investigated 
timespan was only 28 days and the controls were again suboptimal (control subjects were recruited 
by random digit dialing and who agreed to provide one blood sample and some personal 
information). A third study investigating telomere length evolution, found that telomere length in 
breast cancer patients receiving chemotherapy only transiently decreases, with recovery to normal 
age-expected values at 2 years after chemotherapy125. These age-expected values were calculated 
based on a healthy donor group. Telomere length before and after treatment, was obtained in a 
cross-sectional way, so the mean telomere length before treatment, was obtained from other patients 
than those included in the group that yielded the mean telomere length value during or after 
treatment. No comparison with the evolution in matched cancer patients treated without 
chemotherapy was made. The study of Sanoff et al126 did not show increased telomere shortening in 
patients having received chemotherapy. But no control group was included in this study, 
comparisons on telomere dynamics were made using historical controls, and even using data 
obtained from murine experiments.  
 
Taken together, none of the previously published studies on telomere evolution in chemotherapy 
treated patients included a prospectively collected control group of cancer patients. Most 
conclusions were made based upon comparison with historical controls, or healthy volunteers. 
Sometimes, the age ranges of the patients differed greatly, and some studies did not even compare 
the evolution of senescence markers within the same patients (at different time points), but did 
compare absolute values between different patients taken at a fixed time point in a cross sectional 
way. 
 
In our study, we have built a design trying to avoid some important methodological pitfalls. We 
selected our breast cancer patients older than 70 years of age at diagnosis in order to focus on the 
older population. The study group consisted of patients receiving chemotherapy (all the same 
schedule by intention to treat, although ultimately, a few patients switched to another schedule or 
quit therapy due to allergic reactions). Most importantly, we selected a control group that also had 
early breast cancer and also had undergone the same surgical treatment. The only difference with 
the study patients was that the controls were not advised chemotherapy. Herein lies the strength of 
our study: none of the previous studies has managed to obtain samples from a control group 
consisting of comparable cancer patients. Some studies compared to historical controls, others 
selected a healthy age matched group as controls. Their results might have been biased by the 
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difference in morbidity between groups, and also by the difference in previous or ongoing 
treatments like surgery, radiotherapy, …  
Ideally, our patient groups would have been randomized. Due to ethical considerations, it was 
however not possible to randomize patients to either or not chemotherapy. This resulted in a slightly 
less fit control group, as apparent from LOFS and biomarkers at baseline and by long-term 
frequency of hospitalization events. This was not unexpected, since not only patients at low risk for 
cancer recurrence, but also patients too frail for chemotherapy, were included as controls. We 
believe that this does not impact our conclusions as we did not compare absolute values of telomere 
length at a specific time point, but rather considered differences in evolution over time between the 
groups.  
 
Concluding on telomere length, we can state that we did not find a significant increase in telomere 
shortening in the group of patients receiving chemotherapy.  
 
We then looked at evolution of other biomarkers to see if their evolution could corroborate the 
conclusion on telomere length. IL-6, the marker that correlated best with frailty assessment in our 
retrospective study, confirmed our conclusion: there was no chemotherapy-induced difference 
measurable at 1 year of follow up.  
Four of the other biomarkers however, did suggest a slight age-promoting effect: IL-10 and IGF-1 
decreased and TNF-α and MCP-1 increased in the chemotherapy group (all at timepoint 1 year), 
while their values remained more or less stable in the control group.  
The fifth biomarker, RANTES, showed a similar decrease in chemotherapy and control group. 
 
As we commented on the retrospective study, we mention here again the potential value of 
including a cancer-free older control group as third party. It would have added to the scientific 
information on cytokine and chemokine differences induced by the presence of an oncological 
disease, compared to the differences induced by the prescribed cancer treatment. But given the 
results of our retrospective study we believe that the inflammatory changes related to breast cancer 
do not overrule the changes related to aging. In this specific prospective study setting, the tumor had 
been removed surgically before inclusion, and patients were recovering from surgery, waiting for 
radiotherapy in most cases. For making assumptions on the effect of chemotherapy on the aging 
process, we needed control patients that undergo comparable stressors to exclude as much bias as 
possible.  
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We can’t provide an unambiguous rationale explaining the paradoxical findings on telomere length, 
RANTES and IL-6 on the one hand, and the other biomarkers on the other hand. We tend to 
consider the impact of alterations in only a few biomarkers that contribute to the so-called 
‘inflammaging’ phenomenon rather minimal, especially as the more robust aging biomarkers 
(telomere length and IL-6) do not appear to show the same trend. All the more because we did not 
find any clinical signs of accelerated aging at 1 year follow up. Any changes in geriatric assessment 
and quality of life assessment that were noticed at 3 months follow up (and that can be explained by 
the short-term toxicity of chemotherapy), disappeared at 1 year. This highlights another strength of 
our study: next to the panel of biomarkers that was measured, we performed repeated geriatric 
assessments and quality of life questionnaires in all patients to measure the impact of chemotherapy 
on the frailty level and overall quality of life. As we do not have a gold standard measuring 
biological age, we believe that conclusion must not be based on biological markers alone, but must 
take into account clinical correlates. This clinical part was not included in any of the previously 
published studies.  
 
After our prospective study started recruiting patients, the paper by Sanoff et al126 was published. 
They did not only measure telomere length as mentioned previously in this discussion, but they also 
measured the expression of p16INK4A in peripheral blood T-lymphocytes. An increase in p16INK4A 
expression after 1 year was found in chemotherapy treated patients, compatible with acceleration of 
the aging process by chemotherapy. There was no control group included, but expected p16INK4a 
expression values for age were inferred from historical controls and in vitro data. To confirm their 
findings, the authors performed an independent analysis in a cross-sectional cohort of 176 breast 
cancer survivors enrolled after treatment, from which 34% received chemotherapy. This cross-
sectional analysis showed a maintained increase in p16INK4A expression in chemotherapy treated 
patients, at a median 3.4 years after treatment. The methodological limitations of this study have 
already been highlighted. We can add to this that the cross-sectional validation could carry a 
selection bias: more frail patients that did not receive chemotherapy could already have died by the 
time they could have been included in the cross sectional validation, favoring the non-chemotherapy 
group in the p16INK4A measurements. Patients that relapsed from their breast cancer and received 
new chemotherapy for this relapse will also have been excluded, potentially introducing bias. A 
prospectively collected control group minimizes this kind of bias. Most importantly, we would have 
liked to see the clinical repercussion of the described biochemical changes, and the head-to-head 
comparison with a similar cancer patient group not receiving chemotherapy. On our own study 
samples, we evaluated the possibility of measuring the expression of p16INK4A in peripheral blood. 
As we did not plan upfront to measure p16INK4A expression we only decided to collect whole blood 
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RNA throught Paxgene® tubes, and not separate T-lymphocytes immediately after sample 
collection. After the study had already started, we decided to try to measure p16INK4A expression (on 
the total RNA), and extract mathematically how much of this expression could be attributed to the 
lymphocytes, by using the white blood cell formula. Unfortunately, our Paxgene tubes did not yield 
enough RNA in most patients, in order to perform this RT-qPCR, which required a high RNA input. 
That is why we could not investigate p16INK4A expression changes in our study.  
 
Further follow up on the patients in our prospective study will provide clarity whether we can link 
any of the clinical or biological markers to differences in overall survival. Despite the useful 
information that will come from this follow up, we will also have to take into account the cancer-
specific mortality, which might make it difficult to attribute differences in mortality entirely to 
biological aging. Adding a healthy age-matched population would in this regard have been 
interesting. 
 
The main purpose of our study was trying to evaluate the effect of chemotherapy on biological 
aging, which would be compatible with chemotherapy toxicity on the longer term. We also 
performed measurements of biomarkers and geriatric assessment at 3 months, and collected toxicity 
data, in order to evaluate as a secondary endpoint, if one of the clinical or biological aging 
parameters would be predictive of short-term chemotherapy toxicity (grade II-III-IV) in older 
patients. As explained in the introduction, two predictive scoring systems have been developed that 
attempt to predict toxicity of chemotherapy in an older cancer population: the CRASH score113 and 
the Hurria score114. Neither one of the scoring systems however, have managed to get implemented 
into routine clinical practice. Probably because oncologists are not familiar with the Chemotox 
value used in the CRASH score, and because of the complexity of the Hurria score. Moreover, the 
value of these scores for the individual patient is questionable, as they have been developed on a 
heterogeneous cancer population (different cancer types together).  
Apart from febrile neutropenia (13% grade III), we noticed only few grade III, and even no grade 
IV side effects in our chemotherapy population. None of the biomarkers measured at the start of 
treatment, were predictive for toxicity or unplanned readmissions, and neither were the clinical 
frailty scores (Balducci/LOFS). To this secondary endpoint, we must conclude that biomarkers of 
aging can’t be used as prediction for short-term toxicity in breast cancer patients treated with 
Docetaxel-Cyclophosphamide.  
 
In final conclusion to this research project, we state that: 
- Aging in the host translates into differences in stromal characteristics in breast cancers. 
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- IL-6 can be used as frailty biomarker in older breast cancer patients, and leukocyte telomere 
length, MCP-1 and IGF-1 reflect increasing age in this population. 
- Based on the most robust biomarkers of aging (Leukocyte Telomere Length and IL-6) as 
well as on geriatric assessment results, there is no evidence that chemotherapy with 
Docetaxel-Cyclophosphamide would accelerate the rate of biological aging in older breast 
cancer patients 
- Neither biomarkers of aging, nor geriatric assessment parameters, are predictive for short-
term chemotherapy induced toxicity. 
 
 
2. Future perspectives 
 
 
This research project has opened up several new, intriguing questions.  
 
The aging stroma 
 
We have further corroborated the fact that aging in the host is responsible for changes in tumoral 
stroma, and preclinical evidence exists that these changes would be responsible for a different 
tumoral behavior. Our findings do only represent a small step in the entire staircase that must be 
climbed to understand the complex and intense link between cancer and aging. It would be 
interesting to match gene expression data from stroma, with gene expression data from the 
corresponding tumor cells. We have now shown that the stroma displays different gene expression 
characteristics, but by performing gene expression analysis on the corresponding tumor cells, we 
could investigate if this matches gene expression changes in the tumoral compartment. 
Furthermore, investigating the epigenetics in stroma and tumor DNA could provide further 
clarification on the mechanism by which the gene expression differences are caused.  
For this purposes, we have kept the tumor nests that were left after microdissection of the stroma. In 
a next research project, this could be used to extract RNA or DNA. 
 
Biomarkers of aging and chemotherapy influence on the aging process 
 
We have used a comprehensive panel of potential aging biomarkers, but several other biomarkers 
can be considered to evaluate the influence of chemotherapy on the aging process. In the past, we 
have published on MicroRNA’s as easy-to-measure biomarkers of aging in breast cancer patients129, 
and measurements of several of these MicroRNA’s are currently being run on the samples of our 
prospective study. Signs of oxidative stress in the plasma and proteins reflecting telomere damage 
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(cathelicidin-related antimicrobial peptide or CRAMP, stathmin, Elongation Factor - 1α  or EF-1α, 
and chitinase-3-like protein) are currently being evaluated on our retrospective study samples, and 
will be measured in the future on the prospectively collected samples further investigating 
chemotherapy-induced changes in aging biomarkers.  
A specific topic concerns immune-aging: changes in circulating white blood cell subsets combined 
with CMV serostatus, has been shown specifically to reflect aging in the immune system. These 
parameters have been recently measured on whole blood samples that we collected together with 
our plasma, DNA and RNA samples during the prospective study, and data are now being analyzed.  
For what concerns the measurement of p16INK4A expression, we will never be able to overcome the 
fact that we do not have specific T-lymphocyte RNA, but we are currently evaluating the possibility 
of amplifying the available RNA in order to perform expression analysis on the white blood cell 
RNA. These results can afterwards be corrected mathematically for the percentage of lymphocytes 
measured on the day of the blood drawing. In this way, we hope to be able to perform a (be it 
suboptimal) measurement of the evolution of p16INK4A expression during and after chemotherapy in 
our patients. 
 
The ultimate goal of our research work is to improve cancer care for older patients and to provide 
more evidence-based guidelines for treatment decisions. Therefore we should gain more knowledge 
on the aging process, the interaction of the aging process with cancer, and the influence of cancer 
treatments on the aging process. We might ultimately find a combination of clinical and biological 
markers that quantifies the biological age of a person and helps us in making more justified 
treatment decisions.  
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Appendix 1: Example of a Geriatric Assessment 
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G8 
 
 Items Mogelijke antwoorden Score  
A Bent u afgelopen 3 maanden minder gaan eten 
als gevolg van verminderde eetlust, 
spijsverteringsproblemen, problemen bij kauwen 
en/of slikken? 
 
0 = belangrijk verlies van eetlust 
1 = matig verlies van eetlust 
2 = geen verlies van eetlust 
 
 
………... 
B Gewichtsafname gedurende de 3 afgelopen 
maanden 
 
0 = gewichtsafname groter dan 3 kg. 
1 = weet niet 
2 = gewichtsafname tussen 1 en 3 kg. 
3 = geen gewichtsafname 
 
 
………... 
C Mobiliteit 
 
0 = aan bed of stoel gebonden 
1 = in staat zelfstandig uit bed/stoel te 
komen, maar gaat niet naar buiten 
2 = gaat zelfstandig naar buiten 
 
 
………... 
E Neuropsychologische problemen 
 
0 = ernstig dement of depressief 
1 = licht dement of depressief 
2 = geen psychologische problemen 
 
 
………... 
F BMI: (gewicht in kg) / (lengte in m2) 
 
0 = BMI <19 
1 = 19 ≤ BMI < 21 
2 = 21 ≤  BMI < 23 
3 = BMI ≥ 23 
 
 
………... 
H Neemt de patiënt meer dan 3 geneesmiddelen? 0 = ja 
1 = neen  
 
 
………... 
P Vindt de patiënt dat hij gezonder is, of minder 
gezond, dan de meeste mensen van zijn leeftijd? 
 
0,0 = minder gezond 
0,5 = weet niet 
1,0 = even gezond 
2,0 = gezonder 
 
 
………... 
 Leeftijd  0 = > 85 
1 = 80 - 85 
2 = < 80 
 
 
………... 
  
Totaalscore (0-17) 
  
………... 
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GRP 
 
Omcirkel de juiste antwoordcategorie.   
 
RISICO JA NEE 
1. Aanwezigheid van een cognitieve stoornis 2 0 
2. Alleenwonend of geen hulp mogelijk door inwonende partner/familie 1 0 
3. Moeilijkheden bij stappen/transfers of gevallen in de afgelopen 6 maanden 1 0 
4. Hij/Zij werd gehospitaliseerd in de afgelopen 3 maanden 1 0 
5. De patient gebruikt ≥ 5 geneesmiddelen 1 0 
 
Totaalscore (0-6) 
 
 
.................. 
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Demografische gegevens 
 
 
• Leeftijd 
• Geboortedatum 
 
 
………………jaar 
|__|__| / |__|__| / |__|__|__|__| 
 
 
• Geslacht 
 
 
  Mannelijk 
  Vrouwelijk 
 
 
• Burgerlijke status 
 
  Alleenstaand 
  Getrouwd 
  Gescheiden 
  Weduwe / weduwnaar 
  Andere:…………………….. 
 
 
• Woonsituatie 
 
  Thuis:  
  alleen 
  met partner 
  met familielid 
  Service flat 
  ROB / RVT / Woon- en zorgcentrum (WZC) 
  Andere:…………………….. 
 
 
• Opleiding 
 
 
v Naar school geweest tot de leeftijd van …………. jaar 
v Specifieke informatie 
  Basisschool  
  Middelbare school 
  Lager middelbaar (tot 15 jaar) 
Richting:……………………………………………… 
  Hoger middelbaar (tot 18 jaar) 
Richting:……………………………………………… 
  Hoger onderwijs 
Richting:………………………………………………………… 
  Universitair onderwijs 
Richting:………………………………………………………… 
  Ander:……………………………………………………………. 
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ADL 
 
 
WASSEN 
 
  Krijgt geen hulp (stapt alleen in en uit bad of douche) 
  Krijgt hulp bij baden voor het wassen van één lichaamsdeel (zoals rug of been) 
  Krijgt hulp bij baden voor het wassen van meer dan één lichaamsdeel (of kan niet baden) 
 
 
 
 
O 
O 
A 
 
KLEDEN 
 
  Neemt kleding en kleedt zich alleen aan en uit zonder hulp 
  Neemt kleding en kleedt zich alleen aan en uit zonder hulp, behalve voor het sluiten van 
schoenveters 
  Krijgt hulp voor het nemen van de kledij of het zich kleden of blijft gedeeltelijk/volledig niet 
aangekleed 
 
 
 
 
O 
O 
 
A 
 
WC-GEBRUIK 
 
  Gaat alleen naar het toilet, reinigt zichzelf en trekt kledij terug aan zonder hulp (de persoon kan 
een hulpmiddel gebruiken zoals een wandelstok of rolstoel en een bedpan die hij ’s morgens 
leegmaakt) 
  Krijgt hulp om naar het toilet te gaan of om zich te reinigen of in het schikken van kledij of in het 
hanteren van de bedpan 
  Gaat niet naar het toilet voor zijn uitscheiding 
 
 
 
 
O 
 
 
A 
 
A 
 
VERPLAATSEN 
 
  Gaat alleen in en uit bed, komt alleen in en uit de zetel (met eventueel gebruik van kruk / 
wandelstok) 
  Krijgt hulp bij in en uit bed of zetel komen 
  Komt niet uit bed 
 
 
 
 
O 
 
A 
A 
 
CONTINENTIE 
 
  Controleert urine en defecatiefunctie volledig zelf 
  Occasionele accidentjes 
  Supervisie helpt urine- of darmcontrole; blaassonde of incontinent 
 
 
 
O 
A 
A 
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VOEDING 
 
  Voedt zichzelf zonder hulp 
  Eet alleen tenzij voor het snijden van het vlees of het smeren van de boterham 
  Krijgt hulp bij voeding of wordt geheel of gedeeltelijk gevoed door maagsondes en/of infusen 
 
 
 
 
O 
O 
A 
O = onafhankelijk / A = afhankelijk 
 
 
 
Aantal keer onafhankelijk (0-6) 
 
 
………………… 
 
Aantal keer afhankelijk (0-6) 
 
 
………………… 
 
 
  
121 
 
 
IADL 
 
 Score 
 
GEBRUIK VAN DE TELEFOON 
 
  Bedient zich van de telefoon op eigen initiatief (zoekt de nummers op, kiest ze, enz.) 
  Kiest slechts enkele welbekende nummers 
  Neemt de telefoon op maar belt zelf niet op 
  Gebruikt de telefoon helemaal niet 
 
 
 
 
1 
1 
1 
0 
 
 
WINKELEN 
 
  Kan zelfstandig alle nodige boodschappen doen 
  Is alleen voor sommige boodschappen zelfstandig 
  Moet begeleid worden om boodschappen te doen 
  Is volledig ombekwaam om boodschappen te doen 
 
 
 
 
1 
0 
0 
0 
 
VOEDSELBEREIDING 
 
  Kan zelfstandig maaltijden plannen, bereiden en opdienen 
  Kan geschikte maaltijden bereiden indien hij/zij van ingrediënten voorzien wordt 
  Kan bereide maaltijden opwarmen en opdienen of kan maaltijden bereiden maar is niet in 
staat om het aangewezen dieet te volgen 
  De maaltijden moeten voor hem/haar bereid en opgediend worden 
 
 
 
 
1 
0 
0 
 
0 
 
 
HUISHOUDEN 
 
  Zorgt alleen voor het huishouden of doet het met occasionele hulp (bv. voor zwaar 
huishoudelijk werk) 
  Voert lichte dagelijkse taken uit (zoals de vaat doen, het bed opmaken) 
  Voert lichte dagelijkse taken uit maar op occasionele wijze 
  Vergt hulp voor alle huishoudelijke taken 
  Neemt helemaal niet deel aan de huishoudelijke taken 
 
 
 
 
1 
 
1 
1 
1 
0 
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 Score 
 
WASSEN 
 
  Doet zijn/haar eigen was 
  Kan het kleine linnengoed wassen maar vergt hulp voor zwaarder linnengoed zoals lakens of 
handdoeken 
  De was moet door anderen gedaan worden 
 
 
 
 
1 
1 
 
0 
 
 
VERVOER 
 
  Reist zelfstandig met het openbaar vervoer, de taxi of bestuurt eigen wagen 
  Gebruikt de taxi maar geen openbaar vervoer 
  Gebruikt het openbaar vervoer indien begeleid 
  De verplaatsingen zijn beperkt tot taxi of wagen met hulp van een derde 
  Verplaatst zich helemaal niet buitenshuis 
 
 
 
 
1 
1 
1 
0 
0 
 
 
GEBRUIK VAN GENEESMIDDELEN 
 
  Neemt zelfstandig geneesmiddelen in op het gewenste uur en in de voorgeschreven dosis 
  Is in staat zelfstandig geneesmiddelen in te nemen, indien deze op voorhand klaargelegd 
worden 
  Is niet in staat om zelfstandig geneesmiddelen in te nemen 
 
 
 
 
1 
0 
 
0 
 
 
FINANCIEEL BEHEER 
 
  Regelt zelfstandig de financiële zaken (budget, schrijft cheques uit, betaalt de huur en de 
facturen, gaat naar de bank). 
  Is in staat dagelijkse aankopen te doen maar heeft hulp nodig voor zijn/haar bankrekening of 
voor grote aankopen 
  Is onbekwaam om geldzaken te regelen 
 
 
 
 
1 
 
1 
 
0 
 
 
Totaalscore (0-8) 
 
 
……… 
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Valproblematiek 
 
 
1. Algemeen 
 
 
• Bent u gevallen in het afgelopen jaar? 
 
INDIEN JA: hoe vaak:………………………………………………………………………….. 
 
 
JA 
 
NEE 
 
• Heeft u letsels opgelopen ten gevolge van het vallen? 
 
INDIEN JA: welke letsels? 
  ‘Mineure’ letsels 
  ‘Majeure’ letsels 
 
 
JA 
 
NEE 
 
 
2. Timed up and go test (TUG) 
 
 
Resultaat TUG 
 
 
………………………sec. 
 
Resultaat TUG cognitief 
 
 
………………………sec. 
 
 
3. Valangst 
 
 
• Hoe bang bent u dat u het komende jaar zou vallen en een letsel oplopen? 
  Zeer bang 
  Bang 
  Een beetje bang 
  Helemaal niet bang 
• Zijn er zaken die u niet doet omdat u zou kunnen vallen? 
  Nee 
  Ja 
• Zijn er zaken die u niet meer doet omdat u bang bent dat u zou kunnen vallen? 
  Nee 
  Ja 
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EORCT Qlq-C30 
 
Gelieve alle vragen te beantwoorden door het getal te omcirkelen dat het meest van 
toepassing is.  Er zijn geen ‘juiste’ of ‘foute’ antwoorden.   
 
 Helemaal 
niet 
Een 
beetje 
Nogal Heel erg 
1. Heeft u moeite met het 
doen van inspannende 
activiteiten zoals het 
dragen van een zware 
boodschappentas of een 
koffer? 
 
1 
 
2 
 
3 
 
4 
2. Heeft u moeite met het 
maken van een lange 
wandeling? 
 
1 
 
2 
 
3 
 
4 
3. Heeft u moeite met het 
maken van een korte 
wandeling buitenshuis? 
 
1 
 
2 
 
3 
 
4 
4. Moet u overdag in bed of 
in een stoel blijven? 
 
1 
 
2 
 
3 
 
4 
5. Heeft u hulp nodig met 
eten, aankleden, u zelf 
wassen of naar het toilet 
gaan?  
 
1 
 
2 
 
3 
 
4 
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Gedurende de afgelopen week: 
 
 Helemaal 
niet 
Een 
beetje 
Nogal Heel erg 
6. Was u beperkt bij het 
doen van uw werk of 
andere dagelijkse 
bezigheden? 
 
1 
 
2 
 
3 
 
4 
7. Was u beperkt in het 
uitoefenen van uw hobby’s 
of bij andere bezigheden 
die u in uw vrije tijd doet? 
 
1 
 
2 
 
3 
 
4 
8. Was u kortademig? 1 2 3 4 
9. Heeft u pijn gehad?  1 2 3 4 
10. Had u behoefte te rusten? 1 2 3 4 
11. Heeft u moeite met slapen 
gehad?  
1 2 3 4 
12. Heeft u zich slap gevoeld? 1 2 3 4 
13. Heeft u gebrek aan 
eetlust gehad? 
1 2 3 4 
14. Heeft u zich misselijk 
gevoeld? 
1 2 3 4 
15. Heeft u overgegeven?  1 2 3 4 
16. Had u last van 
constipatie?  
1 2 3 4 
17. Had u diarree?  1 2 3 4 
18. Was u moe? 1 2 3 4 
19. Heeft pijn u gehinderd in 
uw dagelijkse 
bezigheden? 
 
1 2 3 4 
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Gedurende de afgelopen week: 
 
 Helemaal 
niet 
Een 
beetje 
Nogal Heel erg 
20. Heeft u moeite gehad met 
het concentreren op 
dingen, zoals een krant 
lezen of televisie kijken?  
 
1 
 
2 
 
3 
 
4 
21. Voelde u zich gespannen? 1 2 3 4 
22. Maakte u zich zorgen? 1 2 3 4 
23. Voelde u zich prikkelbaar?  1 2 3 4 
24. Voelde u zich 
neerslachtig? 
1 2 3 4 
25. Heeft u moeite gehad met 
het herinneren van 
dingen? 
1 2 3 4 
26. Heeft uw lichamelijke 
toestand of medische 
behandeling uw 
familieleven in de weg 
gestaan?  
 
1 
 
2 
 
3 
 
4 
27. Heeft uw lichamelijke 
toestand of medische 
behandeling u belemmerd 
in uw sociale bezigheden?  
 
1 
 
2 
 
3 
 
4 
28. Heeft uw lichamelijke 
toestand of medische 
behandeling financiële 
moeilijkheden met zich 
meegebracht? 
 
1 
 
2 
 
3 
 
4 
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Wilt u voor de volgende vragen het getal tussen 1 en 7 omcirkelen dat het 
meest op u van toepassing is 
 
 Erg slecht                →               Uitstekend 
29. Hoe zou u uw algehele 
gezondheid gedurende de 
afgelopen week 
beoordelen? 
 
1         2         3         4         5         6         7 
 
30. Hoe zou u uw algehele 
“kwaliteit van het leven” 
gedurende de afgelopen 
week beoordelen?  
 
1         2         3         4         5         6         7 
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MMSE 
 
Oriëntatie: 
 
 Maximum 
score 
Score 
In welk jaartal zijn we? 1  
In welk seizoen zijn we? 1  
In welke maand zijn we? 1  
Welke dag is het vandaag? 1  
De hoeveelste is het vandaag? 1  
In welk land leven we? 1  
In welke provincie zijn we nu? 1  
In welke stad zijn we nu? 1  
In welk ziekenhuis zijn we nu? 1  
Op welke verdieping zijn we nu? 1  
 
Inprentingsvermogen: 
 
Wil je de voorwerpen die ik nu zal opnoemen, onthouden; en wil je ze herhalen als ik ze 
opgenoemd heb? 
 
BAL … VLAG … BOOM 
3 
 
aantal 
pogingen: 
 
…….. 
 
…….. 
 
Aandacht: 
 
Wil je van het getal 100 zeven aftrekken, en trek van de uitkomst telkens weer 7 af, tot ik 
stop zeg. 
(93  86  79  72  65)                              …     …     …     …     …  
 
Wil je het volgende woord spellen? Het woord is DORST. 
Kun je het woord DORST nu van achteren naar voren spellen? 
(1 punt voor elke juiste letter op de juiste plaats) 
5 
 
 
 
5 
 
hoogste 
score: 
 
…….. 
 
 
 
 
 
…….. 
 
Geheugen: 
 
Wil je de namen van de 3 voorwerpen die we zopas hebben ingeoefend, herhalen?     
(bal, vlag, boom) 
3  
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Taal: 
 
 Maximum 
score 
Score  
Wat is dit?   (wijs een horloge aan) 
Wat is dit?   (wijs een potlood aan) 
1 
1 
 
Wil je de volgende zin nazeggen: “Noch vis, noch vlees.” 1  
Wil je het volgende uitvoeren: 
“Neem een papier in je rechter-/linkerhand, plooi het dubbel, en geef het aan mij.” 
 
3 
 
Ik ga je iets laten zien, lees wat er op het papier staat, en doe wat er gevraagd wordt.   
(sluit uw ogen) 
 
1 
 
Wil je een korte zin opschrijven?  (waaraan denk je nu?) 1  
Wil je deze figuren hier natekenen? 1  
 
 
 
Totaalscore (0-30) 
 
 
………………………. 
 
 
 
Opmerkingen: 
……………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………… 
 
 
 
 
Sluit  uw  ogen 
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SCHRIJF  EEN  ZIN 
 
 
 
 
 
 
 
 
 
 
 
TEKEN  DIT  NA 
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GDS 
 
Kruis het antwoord aan dat het meest van toepassing is.  Er zijn geen ‘juiste’ of ‘foute’ 
antwoorden.   
 
 Ja Nee 
1.  Bent u over het algemeen tevreden met uw leven?   
2.  Heeft u veel van uw activiteiten en interesses laten vallen?   
3.  Heeft u het gevoel dat uw leven leeg is?   
4.  Verveelt u zich soms?   
5.  Bent u meestal goedgezind?   
6.  Bent u bang dat er u iets ‘ergs’ zal overkomen?   
7.  Voelt u zich meestal gelukkig?   
8.  Voelt u zich soms hopeloos?   
9.  Blijft u soms liever thuis, dan uit te gaan en nieuwe dingen te doen?   
10. Heeft u het gevoel dat u meer moeilijkheden ondervindt met uw 
geheugen, dan de meeste andere mensen van uw leeftijd? 
  
11. Bent u blij nu te leven?   
12. Voelt u zich nogal waardeloos zoals u nu bent?   
13. Voelt u zich vol levensenergie?   
14. Heeft u het gevoel dat uw situatie hopeloos is?   
15. Denkt u dat de meeste mensen het beter hebben dan u?   
 
Totaalscore (0-15) 
 
 
………… 
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MNA 
 
 
Lengte 
 
 
………………..cm 
 
Gewicht 
 
 
………………..kg 
 
 Items Mogelijke antwoorden Score  
A Bent u afgelopen 3 maanden minder gaan eten 
als gevolg van verminderde eetlust, 
spijsverteringsproblemen, problemen bij kauwen 
en/of slikken? 
 
0 = belangrijk verlies van eetlust 
1 = matig verlies van eetlust 
2 = geen verlies van eetlust 
 
 
………... 
B Gewichtsafname gedurende de 3 afgelopen 
maanden 
 
0 = gewichtsafname groter dan 3 kg. 
1 = weet niet 
2 = gewichtsafname tussen 1 en 3 kg. 
3 = geen gewichtsafname 
 
 
………... 
C Mobiliteit 
 
0 = aan bed of stoel gebonden 
1 = in staat zelfstandig uit bed/stoel te 
komen, maar gaat niet naar buiten 
2 = gaat zelfstandig naar buiten 
 
 
………... 
D Hebt u gedurende de afgelopen 3 maanden last 
gehad van mentale spanning (stress) of acute 
ziekteverschijnselen? 
 
0 = ja  
2 = neen 
 
 
………... 
E Neuropsychologische problemen 
 
0 = ernstig dement of depressief 
1 = licht dement of depressief 
2 = geen psychologische problemen 
 
 
………... 
F BMI: (gewicht in kg) / (lengte in m2) 
 
0 = BMI <19 
1 = 19 ≤ BMI < 21 
2 = 21 ≤  BMI < 23 
3 = BMI ≥ 23 
 
 
………... 
  
Totaalscore (0-14) 
  
………... 
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Charlson Comorbidity Index 
 
Comorbiditeit Aanwezig Punten 
Myocardinfarct  1 
Decompensatie  1 
Perifeer vaatlijden  1 
Cerebrovasculaire aandoeningen (met uitzondering van hemiplegie)  1 
Dementie  1 
COPD  1 
Autoimmuunziekte  1 
Ulcus pepticum (slokdarm, maag, duodenum)  1 
Matige leverfunctiestoornissen  1 
Diabetes (zonder complicaties)  1 
Diabetes met eindorgaan schade  2 
Hemiplegie  2 
Matige / ernstige nierfunctiestoornis  2 
Tweede solide tumor (zonder metastasen)  2 
Leukemie  2 
Maligne lymfoom, Multiple myeloom   2 
Matige / ernstige leverfunctiestoornis  3 
Tweede solide tumor (met metastasen)  6 
AIDS  6 
 
Totaal punten (0-37) 
 
  
……………….. 
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Polypharmacie 
 
Gelieve alle geneesmiddelen te noteren die de patiënt genomen in de week voorafgaand aan de diagnosestelling.  
Noteer telkens de eenheidsdosis die van toepassing is.   
 
 Geneesmiddel Eenheidsdosis  
vb. in mg 
1 
  
 
2 
  
 
3 
  
 
4 
  
 
5 
  
 
6 
  
 
7 
  
 
8 
  
 
9 
  
 
10 
  
 
11 
  
 
12 
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Abstract of the Research 
 
The main objective of this doctoral research was to expand the scientific knowledge on the interface between 
cancer and biological aging. Aging is a multifactorial process that is linked in a very complex way to cancer.  
Because this had never been done in tumors spontaneously occurring in human patients, we started by 
studying stromal characteristics of breast cancers arising in young respectively old patients. Based on the 
description of the SASP (senescence associated secretory profile) and AST (autophagy to senescence 
transition) in literature, two phenomena supposed to occur in senescent cells (e.g. fibroblasts), and the 
hypothesis that senescent cells accumulate in the body with aging, tumors arising in older patients could be 
expected to display a stromal compartment with different characteristics, which ultimately could lead to a 
different behavior of the tumor cells. By laser capturing the stromal compartments of breast cancers from 
young and old patients, and comparing the gene expression profiles, we confirmed for the first time in 
humans, the presence of both phenomena in the older breast cancer stromal samples. Moreover, we found 
that the older stromal compartment displays significant differences in gene expression compared to younger 
stroma, which concerned mainly genes responsible for proliferation, dedifferentiation and migration into the 
extracellular matrix.  
In a second part of the thesis, we investigated biological aging in the rest of the organism, and the impact 
from cancer treatment (by chemotherapy) on this process. The main purpose of this research was to provide 
more evidence-based knowledge, allowing incorporation of the concept ‘biological age’ into therapy 
decisions for older patients. To do this, it was important to study the value of several biological markers in 
reflecting the biological age of a patient, as there is no current gold standard for this. In a retrospective study 
investigating several biological and clinical parameters of aging in young and old breast cancer patients IL-6 
showed to be a robust frailty marker. Other markers like Leukocyte Telomere Length, IGF-1 and MCP-1 
showed correlations with chronological age but not with frailty level. During this study we also developed 
the Leuven Oncogeriatric Frailty Score, a tool that summarizes the clinical frailty level of a patient in a more 
subtle way than do the currently used tools like Balducci classification.  
Next, we performed a prospective study in early breast cancer patients either or not treated with adjuvant 
chemotherapy, and tested if the natural evolution of clinical and/or biological aging markers was influenced 
by chemotherapy. We did not find unexpected changes in the evolution of the most robust aging markers 
(Leukocyte Telomere Length and Interleukin-6) which means that we do not find convincing evidence that 
the chemotherapy we studied (Docetaxel-Cyclophosphamide) would accelerate biological aging in breast 
cancer patients. This is a reassuring finding for oncologists treating older patients. As a secondary endpoint, 
we checked if clinical or biological markers were correlated with short-term toxicity from chemotherapy, but 
neither of the aging parameters was useful in predicting grade II-III-IV toxicity, or unplanned hospital 
readmissions. 
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Nederlandse Samenvatting 
 
Dit doctoraatsonderzoek werd opgericht om meer wetenschappelijke inzichten te vergaren over de 
complexe verwevenheid van veroudering als biologisch process, en het optreden van kanker.  
Eerst en vooral werd het micromilieu waarin borstkankercellen groeien onderzocht. Er werd 
nagegaan of dit micromilieu verschilt naarmate de leeftijd van de patient vordert. Er zijn 
verschillende wetenschappelijke gegevens voortkomend uit laboratoriumonderzoek, die dit 
suggereren. Anderzijds leert de klinische ervaring dat borstkanker bij oudere vrouwen meestal een 
trager en minder aggressief ziekteverloop kent.  
We gebruikten de techniek van laser microdissectie om stukjes van dit micromilieu uit 
borstkankergezwellen van oudere en jongere patienten te snijden. Nadien onderzochten we 
verschillen in genexpressie op het bekomen materiaal. We stelden vast dat in het oudere 
micromilieu genen betrokken in celgroei, celmigratie en celdedifferentiatie meer tot expressie 
kwamen. Daarenboven werden enkele belangrijke concepten bevestigd: er bleken in het ouder 
micromilieu tekenen aanwezig van een ‘senescence associated secretory profile’, een fenomeen 
waarbij verouderde cellen allerlei proteines secreteren die tumorgroei kunnen bevorderen. Ook 
tekenen van autofagie-activatie werden aangetroffen in het oudere micromilieu. Ook dit kan 
tumorgroei kan stimuleren. Hoewel deze fenomenen reeds beschreven zijn in preklinisch 
onderzoek, hebben we dankzij dit onderzoek voor het eerst een bewijs geleverd van hun bestaan in 
patienten. 
Verder onderzocht dit doctoraatsonderzoek ook het verouderingsproces in de rest van het lichaam, 
en meer specifiek het effect van een kankerbehandeling met chemotherapie hierop. Er bestaat 
momenteel geen goede test om de biologische leeftijd van een patient te meten.  
We bestudeerden verschillende verouderings-merkers in een groep oudere en jongere 
borstkankerpatienten en vergeleken dit met hun resultaat op een geriatrische evaluatie, een test die 
de mate van hulpbehoevenheid op verschillende functionele vlakken probeert na te gaan. We 
vonden interleukine-6 als biologische merker die het best dit niveau van hulpbehoevendheid 
reflecteert. Enkele andere merkers bleken ook gerelateerd met de leeftijd van de patient. 
In een laatste studie vergeleken we de evolutie van deze biologische merkers, alsook de evolutie 
van de geriatrisch evaluatie, in een groep borstkankerpatiënten die al dan niet behandeld werden 
met chemotherapie. We wilden nagaan of chemotherapie het verouderingsproces doet versnellen. 
We stelden geen veranderingen vast in evolutie van telomeerlengte of interleukine-6, noch in 
geriatrische evaluatie resultaten, bij patiënten die chemotherapie kregen. Andere biologische 
merkers suggereerden mogelijks een beperkt verouderingseffect van chemotherapie, doch gezien de 
meest krachtige verouderingsmerkers niet beinvloed blijken hierdoor, concluderen we dat er geen 
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overtuigende evidentie is dat chemotherapie doet verouderen. 
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